



The tcpCO<sub>2</sub> handbook

Author: Scientific Advisor Annette Melhedegaard Thomsen,  
Radiometer Medical ApS.

Contributor: Prof. Dr. Konrad E. Bloch, Universitäts Spital Zürich.

With input from Kevin Bage, Radiometer LTD, Franz von Wirth,  
Radiometer GmbH and Phil Lazzara, Radiometer America Inc.

Copyright © 2012 Radiometer Medical ApS, Denmark.  
Contents may be reproduced if the source is acknowledged.

Printed in Denmark by Radiometer Medical ApS,  
Åkandevvej 21, 2700 Brønshøj, Denmark, 2011.

ISBN 978-87-91026-09-6  
939-049. 201201E.



Data subject to change without notice.

Radiometer, the Radiometer logo, ABL, AQT, TCM, RADIANCE, AQUIRE, PICO,  
CLINITUBES and QUALICHECK are trademarks of Radiometer Medical ApS.

## Introduction to transcutaneous monitoring

tcpCO <sub>2</sub> /tcpO <sub>2</sub> monitoring .....	6
TC methodology .....	10
Combined measurements of tcpCO <sub>2</sub> SpO <sub>2</sub> .....	12
General TC application advice .....	20
Choice of measuring sites .....	26
Choice of measuring temperature .....	29

## Transcutaneous monitoring applications

Neonatology .....	33
Pediatrics .....	40
Operating room, ICU and step-down units .....	45
Conscious sedation during diagnostic surgery .....	50
Pulmonary/respiratory medicine laboratories or wards .....	54
Sleep laboratories .....	62
Veterinary hospitals/laboratories .....	66

## Use of TCM4/40/TOSCA/CombiM monitors

Menu structure of TCM4/40/TOSCA/CombiM monitors .....	70
Short-form support for:	
<i>The TCM4/40/TOSCA/CombiM monitors</i> .....	71
How to apply TC sensor .....	78
Calibration .....	81
Cleaning .....	84
Maintenance of the sensor .....	86
List of abbreviations .....	93

## Complementary techniques

Choice of sensor site and temperature .....	101
---	-----

# Introduction to transcutaneous monitoring

The transcutaneous carbon dioxide and oxygen measuring techniques were first developed in the nineteen seventies. Since then, major further advances have been made and significantly improved the technology and practical application. Today, monitoring of transcutaneous gas tension is not only valuable for the respiratory and ventilatory status of neonates, but also highly relevant for the ventilatory care of children and adults with chronic respiratory failure. This development has followed the change in hospital care. Trends go in two directions: towards an increased application of non-invasive acute and long-term ventilation, and towards a more frequent use of techniques like high-frequency jet ventilation (HFJV), high-frequency oscillatory ventilation (HFOV) and other novel acute care therapeutic modalities. Together, these changes have led to an increased need for continuous focus on the patient's carbon dioxide (CO<sub>2</sub>) status. Transcutaneous CO<sub>2</sub> monitoring meets these requirements non-invasively.

This handbook is primarily a guide to transcutaneous carbon dioxide (tcpCO<sub>2</sub>) monitoring from a clinical perspective. However, as transcutaneous oxygen (tcpO<sub>2</sub>) monitoring is sometimes relevant for the same patients (e.g. neonates on oxygen), the handbook also contains information on this parameter. For more in-depth information on tcpO<sub>2</sub> monitoring of patients with peripheral arterial disease (PAD), e.g. critical ischemia, please refer to "*The tcpO<sub>2</sub> handbook*". [\*]

\* Thomsen A, Wirth FV, Bryde-Jacobsen J. The tcpO<sub>2</sub> handbook. Radiometer Medical ApS, Åkandevvej 21, 2700 Brønshøj, Denmark, 2003.

As measurement of oxygen saturation by pulse oximetry ( $\text{SpO}_2$ ) is often used in combination with  $\text{tcpCO}_2$ , and sometimes also  $\text{tcpO}_2$  monitoring, this technique is described as well.

The handbook is based on scientific literature and the operator's manuals of Radiometer TCM monitors. According to the findings in clinical studies, the handbook provides suggestions on patient categories for which TC monitoring can be used.

References are found at the end of each section. For a more detailed presentation of technical issues and troubleshooting of transcutaneous monitors, please refer to the operator's manuals of these products.

Each section contains blank pages for the reader to make relevant notes and modifications according to local policies and procedures.

*Note:* The validity of any measurement must be carefully examined by a clinician/healthcare professional and related to the patient's clinical condition before any decisions are made on the basis of the measurement.

## tcpCO<sub>2</sub>/tcpO<sub>2</sub> monitoring

### Continuous non-invasive monitoring

Patients with respiratory and cardiovascular disease, during anesthesia and surgery depend on having their carbon dioxide and oxygen status surveyed. Hypercapnia and hypoxia can result in acidosis requiring treatment; if undetected hypercapnia and hypoxia may lead to acidotic, hyperkalemia, myocardial depression, arrhythmias, arterial hypotension or hypertension, intercranial hypertension, narcosis and organ damage. Hypocapnia and hyperoxia may also have adverse and even severe damaging effects on the brain and other organs due to the vulnerability of cells and organs to changes in blood pH level and their dependence on oxygen. Continuous non-invasive transcutaneous monitoring of carbon dioxide and oxygen may be obtained in various ways and combinations:

6

- tcpCO<sub>2</sub>
- tcpO<sub>2</sub>
- SpO<sub>2</sub>
- tcpCO<sub>2</sub> + tcpO<sub>2</sub>
- tcpCO<sub>2</sub> + SpO<sub>2</sub>
- tcpCO<sub>2</sub> + tcpO<sub>2</sub> + SpO<sub>2</sub>


## Transcutaneous measurement of carbon dioxide and oxygen

Transcutaneous carbon dioxide and oxygen monitoring is a non-invasive way of continuously measuring the tension of these gases in the skin. A combined Clark-type and Severinghaus-type sensor also called Stow-Severinghaus sensor\* is placed on the skin and heated. The sensor heat dilates the underlying capillaries and increases the gas diffusion through the lipid structure of the skin, thereby allowing carbon dioxide and oxygen to diffuse up to 20 times more quickly from the capillaries through the skin to the sensor. The oxygen generates a current and the carbon dioxide a potential in the sensor.

These signals are converted by the monitor and showed as  $\text{tcpCO}_2$  and  $\text{tcpO}_2$  values on the screen.

\*In the literature the  $p\text{CO}_2$  sensor is generally known as a Severinghaus-type sensor. However, Richard Stow originally invented the gas measuring technique and described it in 1954. Later that year, Leland C. Clark Jr. designed an arterial blood gas  $p\text{O}_2$  sensor. In 1958 John W. Severinghaus developed a complete blood gas apparatus by combining his more practical version of Stow's  $p\text{CO}_2$  sensor with Clark's  $p\text{O}_2$  sensor. This is the reason why; the  $p\text{CO}_2$  sensor is also known by the name Stow-Severinghaus sensor. Dietrich Lübbers, Albert and Renata Huch demonstrated together with Patrich Eberhard in 1972 that heating the skin to 42-45° C creates vasodilatation, which makes the cutaneous surface  $p\text{O}_2$  value reasonable close to  $\text{PaO}_2$ , especially in newborn babies. After that were the transcutaneous  $p\text{CO}_2$  sensor also developed and introduced to the market in the early 1980s [1].

## The sensor on the skin




**FIG. 1: Transcutaneous  $p\text{CO}_2/\text{O}_2$  monitoring (TC)**

The heat from the sensor dilates the capillary and increases local blood flow and the diffusion of  $\text{CO}_2/\text{O}_2$  through the skin to the sensor.  $\text{tcpCO}_2/\text{tcpO}_2$  is measured electrochemically inside the sensor.

### Are $\text{tcpCO}_2/\text{tcpO}_2$ identical to arterial blood gases?

It is a misconception that  $\text{tcpCO}_2/\text{tcpO}_2$  are the same as arterial blood gases. The purpose of monitoring transcutaneous gas tensions is to obtain information on the cardio-respiratory condition of a patient without the need to repeatedly draw arterial blood samples for analysis. However, the transcutaneous partial pressure of oxygen reflects the underlying dermal  $p\text{O}_2$  level that is influenced not only by the arterial  $p\text{O}_2$  but depends on local blood flow, oxygen release from hemoglobin and skin metabolism. Living skin will always consume some oxygen and  $\text{tcpO}_2$  will therefore always be lower than the arterial  $p\text{O}_2$  irrespective of the sensor measuring temperature. Similarly, dermal  $p\text{CO}_2$  measured by a transcutaneous sen-





**FIG. 2: Example of the different levels of gases in blood to tissue**

Illustration of the physiological oxygen and carbon dioxide contents in a healthy subject's arterioles, capillaries and skin cells, when the heat from the TC sensor dilates the capillary and increases local blood flow. As part of the metabolic reaction there will be some oxygen consumption and an additional carbon dioxide production.

sor is not only determined by the arterial  $\text{PaCO}_2$  but also influenced by local blood flow, and the skin metabolism. The cells metabolic's  $p\text{CO}_2$  addition is temperature-dependent, this influence is minimized by applying a temperature-specific constant and a metabolic factor; however, there will still be some difference between the  $\text{tcpCO}_2$  value and the carbon dioxide tension in the arterial blood. Generally  $\text{tcpCO}_2$  would be higher than  $\text{PaCO}_2$  [2,3].


### **$\text{tcpCO}_2/\text{tcpO}_2$ measures skin $p\text{CO}_2/p\text{O}_2$**

$\text{tcpCO}_2/\text{tcpO}_2$  monitoring is an easy and non-invasive method that reflects the trends of changes of arterial blood gases. It provides assessment of the tissue's oxygenation and carbon dioxide removal via the cardio-pulmonary system. This information can indicate if an arterial puncture is required [4].

## TC Methodology

### Measurement of carbon dioxide tension


$\text{tcpCO}_2$  measurement is in fact a pH measurement.  $p\text{CO}_2$  from the skin diffuses through the membrane of the sensor into an electrolyte solution. Here it reacts with water, forming carbonic acid that immediately dissociates into  $\text{HCO}_3^-$  and  $\text{H}^+$  according to the following equation:




As  $\text{HCO}_3^-$  in the electrolyte solution is kept at a fixed level, changes in the  $\text{H}^+$  concentration will always be equivalent to changes in pH. These pH changes alter the voltage between the glass sensor and the reference sensor. The measured pH is converted into a carbon dioxide reading by the Henderson-Hasselbalch equation and is shown as a  $\text{tcpCO}_2$  value in either mmHg or kPa [5,6]

### Oxygen measurement

Oxygen from the skin passes through the sensor membrane. It reaches the cathode, which consists of platinum. Here oxygen is reduced as a result of the current-generating process:



The silver ring surrounding the platinum cathode is the anode where the following oxidation reaction takes place:



The reduction of oxygen generates a current that is converted by the monitor into a voltage and a digitized  $\text{tcpO}_2$  value in mmHg or kPa [5,6].

## Notes

1. Severinghaus JW, Astrup P, and Murray JF. Blood gas analysis and critical care medicine. Am J Respir Crit Care Med. 1998; vol. 157; nr. 4: 114-22.
2. Wimberley PD, Frederiksen PS, Witt-Hansen J. *et al.* Evaluation of a transcutaneous oxygen and carbon dioxide monitor in a neonatal intensive care department. Acta Paediatr Scand 1985; 74: 352-59.
3. Wimberley PD, Pedersen KG, Olsson J. *et al.* Transcutaneous carbon dioxide and oxygen tension measured at different temperatures in healthy adults. Clin Chem 1985; 31, 10: 1611-15.
4. Hill KM, Klein DG. Transcutaneous carbon dioxide monitoring. Crit Care Nurs Clin N Am 2006; 18: 211-15.
5. Larsen J, Linnet N. tc 110: Solid state transcutaneous combined  $pO_2/pCO_2$  sensor. Radiometer A/S, Denmark 1990 (ISBN 87-88138-283)
6. TOSCA 500 Operating Manual. Radiometer Basel AG, Radiometer Medical ApS. 2006; Publ. No: 520.81001/3 – issued Jan. Part No.: 520 0910

## Combined measurements of $\text{tcpCO}_2$ and $\text{SpO}_2$

### Combined $\text{tcpCO}_2$ and $\text{SpO}_2$ sensor

Pulse oximetry provides instant and continuous information about oxygen saturation and pulse rate. It does not, however, indicate how much hemoglobin is available in the blood. Oxygen saturation measurement is often used together with  $\text{tcpCO}_2$  as they compliment each other and provide a wider perspective of the patient's blood gas status. Pulse oximetry is widely accepted because of its non-invasive character, ease of use and low cost. It is also considered easy to interpret; however, the technique has certain limitations that are important to keep in mind in order to obtain optimum patient monitoring.


### $\text{SpO}_2$ methodology

A pulse oximeter sensor typically contains two light-emitting diodes (LEDs) – one with red light and one with infrared light. The light passes through a blood-perfused tissue to a photodetector on the other side of the finger, earlobe, foot or toe or is reflected by bone and other structures. The more light-absorbing blood that is present at the moment of measurement, the less light reaches the photodetector [7].

The illustration next page shows a spectrophotometric measurement of blood with an overlap of the red (660 nm) and infrared (900 nm) light. The two absorption peaks represent oxygenated ( $\text{O}_2\text{Hb}$ ) and deoxygenated (HHb) hemoglobin.

Because  $\text{O}_2\text{Hb}$  absorbs less red light than infrared light, the underlying blood flow at high saturation values has less influence on the detected red signal than on the infrared one. At

low saturation values this situation is reversed and far more red than infrared light is absorbed. Thus, the arterial oxygen saturation can be derived from the ratio of the red and infrared light absorption.  $SpO_2$  measurements indicate how much oxygen is actually bound to the available hemoglobin in the blood, but it does not show the hemoglobin or dyshemoglobin concentration. Therefore  $SpO_2$  might not always show the actual blood oxygen status [8].



**FIG. 3: LED-emitted light spectrum**


Overlapping of typical LED-emitted light spectra and relative light absorption spectra of oxygenated and deoxygenated hemoglobin. The dashed purple line indicates the spectrum of 50 % saturated blood, with the relative absorbance in the red and infrared indicated by the black circles. Figure and text is reprinted by permission of Nellcor Puritan Bennett Inc. Pleasanton, California [8].

## The relation between $\text{SpO}_2$ and $p\text{O}_2$

The oxygen dissociation curve describes the relationship between oxygen tension ( $p\text{O}_2$ ) and oxygen saturation ( $\text{SpO}_2$ ) at standard conditions (Fig. 4).


This relationship can be used with some restriction to estimate  $p\text{O}_2$  from  $\text{SpO}_2$ . The position of the dissociation curve is, however, shifted either to the left or the right by changes in pH, temperature, 2,3-DPG,  $p\text{CO}_2$  level, and the presence of dyshemoglobins.

A multicenter study of these variables resulted in the curves shown in (Fig. 5). When oxygen saturation is read from this curve with a  $\text{PaO}_2$  of 8 kPa (60 mmHg), the corresponding  $\text{SpO}_2$  value ranges from 69.7 % to 99.4 %. At  $\text{SpO}_2$  level of 90 %, the  $\text{PaO}_2$  values ranges were 3.82 and 18.3 kPa (29 and 137 mmHg). Beside this inaccuracy in some patients, it is also important to realize that,  $\text{SpO}_2$  cannot differentiate between hypoxemia caused by ventilation/perfusion mismatch and that caused by alveolar hypoventilation. These examples illustrate that oxygen saturation does not always provide a precise estimate of hypo- and hyperoxia. In terms of oxygen transport, however, the oxygen saturation technique together with the hemoglobin measurements is quite important [9,10].



**FIG. 4: Oxygen tension vs. saturation**

The Oxygen Dissociation Curve.  $p_{50}$  is defined as the oxygen tension of half saturation,  $sO_2 = 50\%$



**FIG. 5: Oxygen tension vs. saturation**

The curve from a multicenter study shows the measured oxygen tension vs. the saturation in 10,079 arterial blood samples [9].

### **SpO<sub>2</sub> bias due to motion, level of skin pigmentation**


Motion artifact is often a problem for pulse oximetry and may result in false readings or alarms. A study that compared finger saturation probes and the number of false alarms showed significantly fewer false alarms on the middle finger compared with measurements on the index finger, which is most often used as measuring site.

SpO<sub>2</sub> measurements may also exhibit erroneous readings due to high patient skin pigmentation or nail polish. Some sensors may even show a small bias when measuring on women. Furthermore, correct sensor fixation is very important to ensure optimum light-tissue interaction and thereby reliable measurements [11,12,].

### **Earlobe sensors vs. finger SpO<sub>2</sub> sensors**

A study showed that a combined earlobe tcpCO<sub>2</sub>/SpO<sub>2</sub> sensor detects changes in oxygen saturation significantly earlier than a finger SpO<sub>2</sub> sensor. This can be explained by a difference in the lung-to-ear vs. lung-to-finger circulation time and by differences in the vascularization of the monitored tissue. The signal processing technique, and the use of a heated sensor affect the response time of pulse oximetry as well. Other studies have shown that the earlobe is less affected by systemic vasoconstriction, which also makes the earlobe a good site for transcutaneous carbon dioxide measurement [13,14,15,16,17].






**FIG. 6: SpO<sub>2</sub> response time**

The response time of a heated combined tcpCO<sub>2</sub>/SpO<sub>2</sub> earlobe sensor is faster than that of an unheated finger probe. As a result, the detection of the beginning and end of the desaturation happens 20-30 seconds earlier by the earlobe sensor and the obtained amplitude is nearly two times greater, indicating a larger specificity. This is important for patients with rapid and transient changes in SpO<sub>2</sub> for example sleep apnea. As not only the number of desaturation events but also the degree of these events correlate with the impairment of the cognitive function and with cardiovascular complications. A short response time is essential in order to detect fast changes of the oxygen saturation [15].

## The combined $\text{tcpCO}_2/\text{SpO}_2$ sensor

The combined  $\text{tcpCO}_2/\text{SpO}_2$  sensor pictured below gives fast information of these parameters together with the pulse rate.



**FIG. 7: The  $\text{tcpCO}_2/\text{SpO}_2$  sensor**

$\text{tcpCO}_2/\text{SpO}_2$  is measured by an earlobe sensor attached by a clip. The technique is a combination of the above shown TC technique and a spectrophotometric pulse oximetry measurement. This TC sensor contains a gold shield that protects the membrane, thereby allowing the sensor to provide reliable measurements for up to 14 days without membrane change. Recommended measuring temperature: 42 °C (108 °F).

$\text{SpO}_2$  is widely accepted due to the non-invasive character of the method, its ease of use and low costs – and when the limitations of the oxygen saturation technique are taken into consideration, the results are easy to interpret.  $\text{SpO}_2$  measurement in combination with  $\text{tcpCO}_2$  provides a continuous estimation of the patient's arterial oxygen saturation and of pulse rate together with information on the carbon dioxide tension in the skin and thereby the body's ability to oxygen uptake and to eliminate carbon dioxide via the cardiopulmonary system. All together this provides valuable information of the patient's cardio-respiratory status as an adjunct to decision making on the patient's care.

7. Haymond S. Oxygen saturation; a guide to laboratory assessment. *Clinical Laboratory News* 2006; Feb: 10-12. Reprint on the AACC website: [www.aacc.org](http://www.aacc.org); *Clinical Laboratory News*; Series Articles.
8. Nellcor Puritan Bennett Inc. A technology overview of the Nellcor oximax pulse oximetry system. Web information.
9. Gøthgen IH, Siggaard-Andersen O, Kokholm G. Variations in the hemoglobin-oxygen dissociation curve in 10,079 arterial blood samples. *Scand J Clin Invest* 1990; 50, suppl. 203: 87-90.
10. Poets CF. Pulse oximetry vs. transcutaneous monitoring in neonates: practical aspects. [www.bloodgas.org](http://www.bloodgas.org) 2003; October: Neonatology.
11. Richards NM, Giuliano KK, Jones GJ. A prospective comparison of 3 new-generation pulse oximetry devices during ambulation after open heart surgery. *Respiratory Care* 2006; 51, 1: 29-35.
12. Poets CF, Stebbens VA. Detection of movement artefact in recorded pulse oximeter saturation. *European Journal of Pediatrics* 1997; 156, 10: 808-11.
13. Hickson VM, Mathews GR. Pulse oximeter sensor accuracy. Poster presentation from the ISAMOV 2007 conference (15-17 Mars 2007 Duke University, Durham, North Carolina).
14. Senn O, Clarenbach CF, Kaplan V *et al.* Monitoring carbon dioxide tension and arterial oxygen saturation by a single earlobe sensor in patients with critical illness or sleep apnea. *Chest* 2005; 128, 1291-96.
15. Bloch KE. Tosca – selected case reports. Adipositas-hypoventilation syndrome. 2005; Patient 1: Figure 2: 5. (Linde Medical Sensors AG, Austrasse 25, CH-4051 Basel, Switzerland)
16. Jablonka DH, Aymen A, Stout RG. What is the optimum site to measure the effect of spontaneous ventilation on the pulse oximeters waveform? *ASA annual meeting abstracts* 2004; A-191.
17. Awad AA, Stout RG, Ghobashy AM. Analysis of the ear pulse oximeter waveform. *Journal of Clinical Monitoring and Computing* 2006; 20, 3: 174-84.

## General TC application advice

### Practical application

An ideal TC measuring site is an area of skin over a homogeneous capillary bed with no large veins, skin defects or hair. Placing the sensor directly on top of a bone or a scar may cause erroneous results because of locally impaired perfusion of these sites. Severe edema may also lead to unreliable results because of the reduction of blood flow caused by a compression of the capillary loops and a longer diffusion pathway. For more information, refer to the section on measuring sites on page 26.

### The sensor

The sensor must be in contact with the skin through the contact liquid or gel. This is to avoid bias from atmospheric air between tissue and sensor. If there are air bubbles, they will affect the measurement, resulting in too high oxygen and too low carbon dioxide levels. For more information, refer to the section on how to apply the TC sensor on page 78.


### Initiation of TC monitoring involves sensor stabilization time

It takes about 3-7 minutes after the sensor has been placed on the skin for the  $\text{tcpCO}_2$  values to stabilize and it may take a further 10-17 minutes to obtain reliable  $\text{tcpO}_2$  values. Preheating the skin may reduce this time to 3-6 and 5-16 minutes, respectively.  $\text{tcpCO}_2/\text{tcpO}_2$  is considered stable when TC values during stable patient conditions do not change more than about  $\pm 2$  mmHg ( $\pm 0.25$  kPa) within 1 minute.

### tcpCO<sub>2</sub> lag and response time

A study in healthy subjects evaluated tcpCO<sub>2</sub> lag time and defined it as: "The time from the initiation of an intervention of the gas status to the initial response of the sensor". The mean lag time for tcpCO<sub>2</sub> during hypercapnia was  $16.8 \pm 1.3$  seconds. When the subjects resumed breathing room air from hypercapnia, the mean lag time was  $14.2 \pm 1.4$  seconds.


The response time may be defined as: The initiation of an intervention in the gas status to the maximum (100 %) response of the sensor. The 90 % response time was  $77.9 \pm 6.7$  seconds. tcpCO<sub>2</sub> has a shorter response time compared with tcpO<sub>2</sub>. This is most likely due to a hypercapnia-induced increased cardiac output, capillary perfusion and faster carbon dioxide diffusion through the epidermis [18].



**FIG. 8: The tcpCO<sub>2</sub> response and lag time**

## UV light

Measurements of  $\text{tcpCO}_2$  and  $\text{SpO}_2$  may be affected by bright light from an UV lamp, e.g. used for jaundiced neonates undergoing light therapy. Some sensors are better shielded from UV light than others; however, additional shielding is still recommended [19].



## MRI-scanning

To minimize the risk of an electromagnetic field interfering with the TC measurements, the TC monitor must always be placed in a safe distance to the MRI-scanner. For TC measurements during MRI-scanning the relevant length for the sensor extension cable can be calculated with support from the TCM operator's manual.

## Vasoconstriction

There is some disagreement about the reliability of  $\text{tcpCO}_2$ / $\text{tcpO}_2$  in cases of epidermal vasoconstriction caused by vasoconstricting agents, toxins in sepsis patients, hypothermia or elevated cutaneous vascular resistance as seen in patients with hypovolemic or cardiogenic hypotension and low cardiac output. Several studies have documented that vasoactive substances like dopamine, tolazoline, isoproterenol, nitroprusside, aminophylline, hydralazine, epinephrine, dobutamine, phenylephrine and norepinephrine did not affect  $\text{tcpCO}_2$ / $\text{tcpO}_2$  measurements [20,21,22, 23].

In a coexisting study, that confirms that the above-mentioned catecholamines did not affect TC measurements, the authors conclude: "However, in cases with profound skin vasoconstriction or shock the correlation between  $tcpCO_2$  and  $PaCO_2$  is low\* ". In these situations low  $tcpO_2$  may be the first warning of a developing hypotensive shock [22,24\*,25].

Smoking and chewing nicotine gum have been observed to decrease the  $tcpO_2$  value for up to 50 minutes, while  $tcpCO_2$  remained unaffected [26].

### **Skin temperature**

A relatively large  $tcpCO_2$  to  $PaCO_2$  bias has been observed under hypothermic conditions, defined as patients with a rectal temperature lower than 36 °C (97 °F) [24].

### **Body mass index**

Some studies suspect that skin thickness in severely obese adults affect the permeability for carbon dioxide diffusion and the vasodilatation of the underlying capillaries from the heating element in the TC sensor. However, several studies have confirmed that  $tcpCO_2$  is not influenced by body mass index; on the contrary,  $tcpCO_2$  has been reported to be the same in both obese and lean individuals [21,22,27].

### **Pigmentation**

$tcpCO_2/tcpO_2$  measurement is based on an electrochemical measurement of carbon dioxide and oxygen diffusing through the skin. As the TC technique does not use light, as used in  $SpO_2$  measurements, it can be used for patients of all races without any bias caused by different levels of skin pigmentation [21].

## Age influences the respiration

The aging process is associated with an increased risk of hypercapnic respiratory failure in patients with pneumonia, congestive heart failure or exacerbation of chronic obstructive pulmonary disease (COPD). The increased  $\text{PaCO}_2$  may be related to the age-related decrease in both respiratory muscle strength and compliance of the respiratory system, as well as to a lower response of the respiratory center etc. A  $\text{tcpCO}_2$  study on respiratory patients aged 66-97 years has shown a high correlation with  $\text{PaCO}_2$  and a low bias. The authors write, "the limit of agreement was compatible with clinical use (8.3-8.5 mmHg/1.1 kPa)". Furthermore, the heat (43°C (109 °F) from the sensor was shown to be well tolerated by older patients, even after recordings at the same measuring site for up to 8 hours [27].

## Neonatal TC correction factor

Some doctors recommend that the metabolic correction factor on the TC monitor is changed from the standard -4 or -5 mmHg (-0.5 or -0.65 kPa) to -8 or -10 mmHg (-1 or -1.3 kPa) for neonatal measurements. This is due to the infant skin structure. The difference in skin structure is also the reason why transcutaneous carbon dioxide and especially transcutaneous oxygen have a much higher  $\text{PaCO}_2/\text{O}_2$  correlation in neonates than in adults.

### The operational conditions

It is recommended to have standard conditions in order to get reliable results:

- Ambient temperature of 5-40 °C (41-104 °F)
- Relative humidity of 20-80 %.



18. Kesten S, Chapman KR, Rebuck AS. Response characteristics of a dual transcutaneous oxygen/carbon dioxide monitoring system. *Chest* 1991; 5: 1211-14.
19. Myers CS. Measured results: Pulse oximetry is proving the simple solution to many COPD disease management programs' success. *The Journal for Respiratory Care Practitioners* 1996; Aug./Sep.: RT 83-86.
20. Palmisano BW, Severinghaus JW. Transcutaneous  $p\text{CO}_2$  and  $p\text{O}_2$ . a multi-center study of accuracy. *J Clin Monit* 1990; 6: 189-95.
21. Bendjelid K, Schütz N, Stotz M et al. Transcutaneous  $p\text{CO}_2$  monitoring in critically ill adults: Clinical evaluation of a new sensor. *Crit Care Med* 2005; 33, 10: 2203-06.
22. Janssens J-P, Howarth-Frey C, Chevrolet J-C et al. Transcutaneous  $p\text{CO}_2$  to monitor noninvasive mechanical ventilation in adults. *Chest* 1998; 113: 768-73.
23. Berkenbosch JW, Lam J, Burd RS et al. Noninvasive monitoring of carbon dioxide during mechanical ventilation in older children: End-tidal versus transcutaneous techniques *Anesth Analg (Pediatric Anesthesia)* 2001; 92: 1427-31.
24. Rodriguez P, Lellouche F, Aboab J et al. Transcutaneous arterial carbon dioxide pressure monitoring in critically ill adults patients. *Intensive Care Med* 2006; 134: 309-12.
25. Rodriguez P, Lellouche F, Aboab J et al. Transcutaneous arterial carbon dioxide pressure monitoring in critically ill adults patients, supplementary material. <http://dx.doi.org/10.1007/s00134-005-0006-4>
26. Strauss MB, Winant DM, Strauss AG et al. Cigarette smoking and transcutaneous oxygen tensions: A case report. *Undersea Hyperbaric Medical Society* 2000; 27, 1: 43-46.
27. Janssens J-A, Laszlo A, Uldry C et al; Non-invasive (transcutaneous) monitoring of  $p\text{CO}_2$  (tcp $\text{CO}_2$ ) in older adults. *Gerontology* 2005; 51: 174-78.

## Choice of measuring sites


### Optimum measuring sites

Optimum transcutaneous measuring sites are areas with good skin perfusion. Generally, the best reflection of central arterial  $p\text{CO}_2/p\text{O}_2$  is obtained with a chest position of the sensor and with high temperature settings (max. 44 - 45 °C).

### Preparing the measuring site

The selected site should be without large veins, skin defects, hair or fat from oil, cream or fetal fat. If necessary, shave and wash the site with alcohol. Placing the sensor directly over a bone may cause erroneous results. Severe edema will also result in unreliable results.

Do not place the sensor directly on previous operation sites, e.g. on patients who have had heart, lung or breast surgery. Local perfusion at these sites is lower due to scar tissue. It is not recommended to use TC sensors on patients with severe dermatological problems such as seen in areas of skin damage due to Prednisolone treatment, burns or allergic reactions etc.



### **tcpCO<sub>2</sub> and tcpO<sub>2</sub> measuring sites**

- Earlobe (Single tcpCO<sub>2</sub> or combined tcpCO<sub>2</sub>/SpO<sub>2</sub> sensor)
- Face (\*)
- Laterally on the neck (seldom used)
- Chest, in the intercostal space (provides the best reflection of PaO<sub>2</sub>/PaCO<sub>2</sub>)
- Lateral abdomen on skinny adults or on children and neonates
- Back (mostly on neonates)
- Ventral side of the upper arm and forearm
- Seat (mostly on neonates or for ischemia patients)
- Thigh (for tcpO<sub>2</sub> measurements on babies or PAOD patients)
- Legs (only for diagnosis of PAD/ischemia)

### **Change measuring sites**

Because the sensor is heated this may cause local hyperemia of the skin, which may disappear within 5-15 minutes. However, on patients with delicate skin this local hyperemia may last for up to 24 hours or longer. If the sensor is left on the same site too long there is a risk of burns. Therefore, it is necessary to change measuring site regularly. For more information, refer to the section on choice of measuring temperature on page 29.

### **TC monitoring on neonates and children**

Neonates and small children have very thin skin that allows measuring on the back and on the bottom with good results. At the same time they are more vulnerable to the heat from the sensor. Therefore it is important to either lower the measuring temperature or to change sensor site more frequently, especially when measuring on very preterm infants. This may be done

(\* Some doctors do not want to use this site because of the risk of skin reactions)

by attaching two or three fixation rings to the infant and then change sensor position between these rings. Remember to dry the fixation - well and refill it again before use. Altogether this will disturb the infants as little as possible. The fixation rings should however, be removed from the skin every 12-24 hours, depending on the condition of the skin [19].

Avoid direct pressure on the sensor

Direct pressure should never be placed on the sensor while it is on the patient, and the patient should never lie on the sensor. Direct pressure may cause invalid measurements and/or cause skin necrosis.

## Notes

## Choice of measuring temperature

### Optimum transcutaneous measuring temperature

The optimum transcutaneous measuring temperature is 42-45 °C (108-113 °F). However, measuring time and skin diffusion conditions are important when choosing the temperature.

- The best reflection of central arterial  $pO_2/pCO_2$  is obtained with a high sensor temperature, i.e. 44 °C (111 °F)
- The higher the temperature, the shorter the response time
- Skin diffusion depends on the patient. The thin skin of neonates and children makes it possible to obtain reliable measurements at lower temperatures than on adults

(tcpCO<sub>2</sub>/tcpO<sub>2</sub> values can be obtained at low temperatures like 37-38.5 °C (99-101 °F) but the measured values do not reliably reflect arterial blood gases and these low measuring temperatures are therefore only used in special pharmaceutical research settings.)

### Reducing risks of skin reactions

To reduce the risk of burns it is necessary to change the measuring site regularly and/or use a lower sensor temperature. A good correlation of the measurement can still be obtained by choosing a high initial temperature of 43-45 °C (109-113 °F) for the first 5 minutes; a feature that is automatic in some monitors. This will increase the dilatation of the underlying capillaries and the gas diffusing through the lipid structure in the skin. This will be the case also after the temperature automatically has been lowered again when using a smart heat function [3].

Patients with the following clinical conditions have higher risk of getting burns from the electrode:

- Shock
- Very low blood pressure
- Distinct systemic vasoconstriction
- Very sensitive skin

## Neonates and children

On neonatal and children's wards it is common to choose a  $\text{tcpCO}_2/\text{tcpO}_2$  sensor temperature of 42.5-43 °C (108-109 °F) for 2-4 hours, or 44 °C (111 °F) for a maximum of 2 hours. For very preterm neonates a temperature as low as 42 °C (108 °F) may be the optimum choice [28,29].

Transcutaneous carbon dioxide in neonates has been shown to have a close correlation with  $\text{PaCO}_2$  at a sensor temperature of 40-44 °C (100-111 °F). However, transcutaneous oxygen is best measured at a higher sensor temperature of 42-44 °C (108-111 °F) [27].

A switch on Smart Heat function, which increases the temperature by 1 °C (1.8 °F) for the first five minutes of measuring, can only be recommended for infants with a weight above 1,000 g. [28].

*Note:* The physiological stabilization time of the sensor is 15-20 minutes for the  $\text{tcpO}_2$  reading and 3-7 minutes for the  $\text{tcpCO}_2$  reading. During this time the sensor will slowly heat the skin, making the arteries dilate. Longer stabilization time may indicate a need for changing the membrane of the sensor. Other reasons could be an incorrect attachment of the sensor, a poorly selected measuring site or an old sensor.

## Adults

On adults the optimum  $\text{tcpCO}_2/\text{tcpO}_2$  temperature and measuring time is 44-45 °C (111-113 °F) for up to 4 hours. However, when there is a need for longer measuring periods of  $\text{tcpCO}_2$  only, the literature often refers to temperatures around 43 °C (109 °F), depending on patient skin condition. Many sleep laboratories use temperature settings of 42-43 °C (108-109 °F) [30].

A study has shown that a sensor temperature of 43 °C (109 °F) was well tolerated for 5-8 hours of continuous monitoring [30].

### Single tcpCO<sub>2</sub>/combined tcpCO<sub>2</sub>/SpO<sub>2</sub> earlobe sensor

Please note that with a single tcpCO<sub>2</sub> or combined tcpCO<sub>2</sub>/SpO<sub>2</sub> earlobe sensor it is possible to obtain reliable adult carbon dioxide estimation at 42 °C (108 °F) for more than 8 hours without changing measuring sites or calibrating the sensor [21].

### Notes

---

---

---

---

---

---

---

---

---

---

3. Wimberley PD, Pedersen KG, Olsson J. Transcutaneous carbon dioxide and oxygen tension measured at different temperatures in healthy adults. Clin Chem 1985; 31, 10: 1611-15.
21. Bendjelid K, Schütz N, Stotz M *et al.* Transcutaneous pCO<sub>2</sub> monitoring in critically ill adults: Clinical evaluation of a new sensor. Crit Care Med 2005; 33, 10: 2203-06.
27. Janssens J-A, Laszlo A, Uldry C *et al.* Non-invasive (transcutaneous) monitoring of pCO<sub>2</sub> (tcpCO<sub>2</sub>) in older adults. Gerontology 2005; 51: 174-78.
28. Lundstrøm KE. Continuous blood gas monitoring in neonates and infants. Radiometer Medical ApS, Åkandevvej 21, 2700 Brønshøj, Denmark, 2005 (928-408). 200502B 1-16, ([www.tc-monitoring.com](http://www.tc-monitoring.com)).
29. Rüdiger M, Töpfer, Hammer H *et al.* A survey of transcutaneous blood gas monitoring among European neonatal intensive care units. Neonatal Intensive Care 2007; 20, 3: 37-40.
30. Frederiksen PS, Wimberley PD, Melberg SG *et al.* Transcutaneous pCO<sub>2</sub> at different temperatures in newborns with respiratory insufficiency: Comparison with arterial pCO<sub>2</sub>. In: Continuous transcutaneous blood gas monitoring. Huch R; Huch A. New York: Marcel Dekker inc.; 1983: p. 233-40.

# Transcutaneous monitoring applications

## A wide range of patients

Transcutaneous monitoring can be used in a number of different patient segments. Historically, the technique has grown from a reliable and beneficial tool for monitoring the carbon dioxide and oxygen situation of neonates to a method that is applicable for many cardiovascular and respiratory patients of all ages. Apart from wound care and hyperbaric medicine, where the main focus is on local  $\text{tcpO}_2$  measurement, a growing number of physicians have become aware of the benefit of reliable  $\text{tcpCO}_2$  measurements.

In this part of the handbook the use of  $\text{tcpCO}_2$  monitoring (and to some extent  $\text{tcpO}_2$ ) in the following clinical setting applications is described:

- Neonatology
- Pediatrics
- Operating room, ICU and step-down units
- Pulmonary/respiratory medicine laboratory or wards
- Sleep laboratories
- Veterinary hospitals/laboratories



# Neonatology

## Why it is essential to monitor arterial $p\text{CO}_2/p\text{O}_2$

Continuous monitoring of both carbon dioxide and oxygen is essential in ill neonates. Changes may occur fast. With intermittent monitoring or repeated blood gas analysis, these changes can go undetected, and may eventually result in organ damage [28].

## Decreased arterial carbon dioxide

Decreasing  $\text{PaCO}_2$  results in decreased cerebral blood flow and several studies on neonates have demonstrated a strong correlation between low  $\text{PaCO}_2$  and adverse cerebral outcome. At values of 22.5 mmHg (3.0 kPa) or less, damage can occur within a few minutes, but also exposure to slightly higher partial pressures (mmHg) for a longer period of time may be dangerous. Therefore, it is important to monitor carbon dioxide levels [28,31,32,33].

## Reducing the number of blood samples

Analysis of arterial blood samples provides accurate estimates of blood gases. However, they provide a momentary picture of the status only. Repeated sampling may not only disturb and stress the neonate, it may also cause the need for a blood transfusion. A significant change in cerebral circulation and thereby oxygenation is documented in relation to sampling from umbilical artery catheters. The number of blood samples should therefore be reduced to an absolute minimum and be combined with transcutaneous monitoring of carbon dioxide and oxygen. The TC technique provides continuous information on the neonate's ability to supply oxygen to the tissue and remove carbon dioxide in the tissue via the cardiopulmonary system. The TC technique follows the trend and changes of these gases [28,34].

## Hypocapnia and lung damage

Hyperventilation results in hypocapnia. Low  $p\text{CO}_2$  before surfactant treatment as well as during ventilation treatment has shown to correlate with the development of chronic lung disease in the preterm infant. In the ventilated preterm infant, it is therefore recommended to monitor  $p\text{CO}_2$  continuously to minimize the risk of lung damage [28,35].

## Ventilation

Ventilation may cause a pneumothorax, and an early diagnosis is likely to improve patient outcome. Unfortunately, this diagnosis is often made rather late. A study showed that the median time from onset to clinical diagnosis was 127 minutes. An elevated  $\text{tcpCO}_2$  without any change in oxygenation may be an indicator of this condition. As  $\text{tcpCO}_2/\text{tcpO}_2$  continually follows the changes in carbon dioxide and oxygen tension with only a short delay, faster intervention is made possible [28,36]

### $\text{tcpCO}_2$ vs. end-tidal $p\text{CO}_2$

A study that compared end-tidal  $p\text{CO}_2$ ,  $\text{PaCO}_2$  and  $\text{tcpCO}_2$  showed that the difference between end-tidal  $p\text{CO}_2$  and  $\text{PaCO}_2$  significantly increased during one-lung ventilation, as one lung ventilation impairs ventilation/perfusion matching. The study showed that  $\text{tcpCO}_2$  reflected  $\text{PaCO}_2$  better than end-tidal  $p\text{CO}_2$  [37]. In infants with cardiopulmonary disease, end-tidal  $p\text{CO}_2$  has been shown to have a poor correlation with arterial values and should therefore not be used. These patients are, according to several studies, more effectively monitored by  $\text{tcpCO}_2$  [37,38,39].

*Note:* In patients with Patent Ductus Arteriosus and right-to-left shunt,  $\text{tcpO}_2$  will be higher on the upper part of the thorax than on the lower part. In these patients the sensor should be placed on the lower back or abdomen or on the thigh. Furthermore, arterial blood samples for validation should always be drawn from the same side of the shunt as the  $\text{tcpCO}_2$  value is being measured [40,41].

## High Frequency Oscillatory Ventilation (HFOV)

Since only the proximal airway pressure is monitored during high-frequency oscillatory ventilation (HFOV), no alarm will occur if there are either an obstruction or restriction of the airway. The technique also induces a risk of hyperventilation resulting in hypocapnia. Therefore many manufacturers of HFOV recommend continuous measurements of  $\text{tcpCO}_2/\text{tcpO}_2$  and  $\text{SpO}_2$  during this form of treatment. This is particularly important in larger children, who have more dead space and a greater metabolic demand when on ventilation [42].

## Hyperoxia in infants

In newborn preterm infants hyperoxia reduces cerebral blood flow for hours after oxygen status has normalized. At the same time hyperoxia has a toxic effect on the lungs and may possibly cause retinopathy in preterm infants. Monitoring  $\text{tcpO}_2$  provides a method of early detection of hyperoxia, which may not be detected by transcutaneous  $\text{SpO}_2$  measurement [28,43,29].



### Clinical guidelines on TC measurements

The relevance of transcutaneous monitoring is substantiated by the American Association for Respiratory Care (AARC) guidelines and the National Clearinghouse Guidelines (US).

36

#### **AARC guidelines and National Clearinghouse Guideline (US)**

According to the AARC practice guidelines, transcutaneous blood gas monitoring of neonatal and pediatric patients should be used if there is a:

- need to monitor the adequacy of arterial oxygenation and/or ventilation
- and/or*
- need to quantitate the response to diagnostic and therapeutic interventions as evidenced by  $tcpCO_2$  and  $tcpO_2$  values

The guidelines point out that  $\text{tcpCO}_2/\text{tcpO}_2$  is appropriate for continuous and prolonged monitoring, e.g. during mechanical ventilation, continuous positive airway pressure (C-PAP) and supplemental oxygen administration. Furthermore,  $\text{tcpO}_2$  can be used for diagnostic purposes as in the assessment of functional shunts, e.g. in neonates with persistent pulmonary hypertension or persistent fetal circulation, or to determine the response to oxygen challenge in the assessment of congenital heart disease [41, 44].

Please note that during ventilation studies the sensor site and an arterial sampling site in patients with functional shunts should be on the same side of the shunt [41,44].

Transcutaneous blood gas monitoring should be applied continuously to develop trending data. So-called spot checks (intermittent short measuring periods) are not appropriate [41,44].





28. Lundstrøm KE. Continuous blood gas monitoring in neonates and infants. Radiometer Medical ApS, Åkandevvej 21, 2700 Brønshøj, Denmark, 2005 (928-408). 200502B 1-16, ([www.tc-monitoring.com](http://www.tc-monitoring.com)).
29. Rüdiger M, Töpfer, Hammer H *et al*. A survey of transcutaneous blood gas monitoring among European neonatal intensive care units. *Neonatal Intensive Care* 2007; 20, 3: 37-40.
30. Frederiksen PS, Wimberley PD, Melberg SG *et al*. Transcutaneous  $p\text{CO}_2$  at different temperatures in newborns with respiratory insufficiency: Comparison with arterial  $p\text{CO}_2$ . In: Continuous transcutaneous blood gas monitoring. Huch R; Huch A. New York: Marcel Dekker inc.; 1983: p. 233-40.
31. Graziani LJ, Spitzer AR, Mitchell DG *et al*. Mechanical ventilation in preterm infants. Neurosonographic and developmental studies. *Pediatrics* 1992; 90: 515-22.
32. Greisen G, Vannucci RC. Is periventricular leucomalacia a result of hypoxic-ischaemic injury? Hypocapnia and the preterm brain. *Biol Neonate* 2001; 79: 194-200.
33. Ambalavanan N, Carol WA. Hypocapnia and hypercapnia in respiratory management of newborn infants. *Clinics in Perinatology* 2001; 28, 3: 517-31.
34. Roll C, Hüning B, Käunike M *et al*. Umbilical artery catheter blood sampling decreases cerebral blood volume and oxygenation in very low birthweight infants. *Acta Paediatr* 2000; 89: 862-66.
35. Garland JS, Buck RK, Allred EN *et al*. Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome. *Arch Pediatr Adolesc Med* 1995; 149, 6: 617-22.
36. McIntosh N, Becher JC, Cunningham S *et al*. Clinical diagnosis of pneumothorax is late: Use of trend data and decision support might allow preclinical detection. *Pediatr Res* 2000; 48, 3: 408-15.
37. Wilson J, Russo P, Russo JA *et al*. Noninvasive monitoring of carbon dioxide in infants and children with congenital heart disease: End-tidal versus transcutaneous techniques. *J Intensive Care Med*. 2005; 20, 5: 291-95.
38. Short JA, Paris ST, Booker PD *et al*. Arterial to end-tidal carbon dioxide tension difference in children with congenital heart disease. *Br J Anaesth* 2001; 86, 3: 349-53.
39. Carter BG, Wiwczaruk D, Hochmann M *et al*. Performance of transcutaneous  $p\text{CO}_2$  and pulse oximetry monitors in newborns and infants after cardiac surgery. *Anaesth Intensive Care* 2001; 29: 260-65.
40. Poets CF. Pulse oximetry vs. transcutaneous monitoring in neonates: Practical aspects. [www.bloodgas.org](http://www.bloodgas.org) 2003; October: Neonatology.
41. Sitting SE. AARC clinical practice guideline; transcutaneous blood gas monitoring for neonatal & pediatric patients – 2004 revision & update. *Respiratory Care* 2004; Sep. 49, 9: 1069-72.
42. User's manual for SensorMedics, Critical Care; Clinical Guidelines for 3100A HFOV chapter 8.1 (version 0595H)
43. Lundstrøm KE, Pryds O, Greisen G. Oxygen at birth and prolonged cerebral vasoconstriction in preterm infants. *Arch Dis Child* 1995; 73: F81-F86.
44. American Association for Respiratory Care. Transcutaneous blood gas monitoring for neonatal & pediatric patients – 2004 revision and update; American Association for Respiratory Care. [www.guideline.gov](http://www.guideline.gov)

## Pediatrics

### Transcutaneous $p\text{CO}_2/p\text{O}_2$ monitoring in children

Transcutaneous monitoring of carbon dioxide and oxygen tension has shown to be clinically relevant in respiratory ill newborns as well as in children in all ages [45,46,47].

The cerebrovascular carbon dioxide reactivity in young children is comparable to that of the newborn, and the risk of hypo-capnia-induced cerebral ischemia in children is similar to that in neonates. Because of this, continuous monitoring of carbon dioxide tension is necessary in both patient groups [28,48].

### Respiratory Syncytial and other Virus infections

Among small children, Respiratory Syncytial Virus infections pose a risk of serious respiration insufficiency, and it is the most frequent cause of hospitalization in many countries [49,50].

Many children are uncomfortable or even afraid of the staff and equipment in hospital. It is well known that this fear can persist for a long time after leaving hospital. Therefore in children's wards it is even more important to minimize the invasive surveillance, and transcutaneous monitoring of carbon dioxide and oxygen tension trends allows non-invasive respiratory surveillance.

### Respiratory support

Transcutaneous blood gas monitoring is an important adjunct to detect the need for and to guide assisted ventilation. In addition, it helps to detect complications such as obstruction either in the ventilation equipment or in the upper airways.



## Obstructive sleep apnea and other sleep related breathing disorders

During polysomnography for evaluation of pediatric obstructive sleep apnea (OSA) and sleep related hypoventilation,  $tcpCO_2$  as well as end-tidal  $pCO_2$  can be used. Several studies have shown that gas exchange is efficiently monitored with  $tcpO_2$ / $tcpCO_2$  in children with COPD during sleep.  $tcpCO_2$  is particularly useful for children who do not tolerate a nasal sampling tube and for those with moderate to severe partial airway obstruction, tachypnea or increased physiological dead space, where end-tidal  $pCO_2$  underestimates the arterial  $pCO_2$  level.  $tcpCO_2$  has been shown to provide an accurate estimation of  $PaCO_2$  over a wide range of carbon dioxide values in young and older pediatric patients with respiratory failure [23,51,52,53].

## Asthma


WHO estimates that 300 million people (children and adults) suffer from asthma and 2.550.000 people died of asthma in 2005. Asthma is the most common chronic disease among children and the numbers are increasing. One example: From 1980 to 1994 the prevalence of asthma in the US increased more than 160 % in children under 5 years of age, and a total of more than 9 million US children under 18 have been diagnosed with the disease (1998). In these patients a challenge test of the lung function may be necessary [54,55].



## Lung function measurements

A 20 % fall in  $\text{tcpO}_2$  can be used as the only indicator for a bronchial reaction during a histamine bronchial provocation test in awake, young children. Ventilation changes evaluated by  $\text{tcpCO}_2$  measurements makes it possible to distinguish between a fall in oxygen tension due to an early, "false" reaction as a result of hypoventilation, and a "true" bronchial reaction. [56].

A study on lung function measurements in awake 2 to 6 year old children has documented that lung function can be assessed by transcutaneous measurements, forced oscillation technique ( $\text{Rrs5}^*$ ), whole-body plethysmography ( $\text{sRaw}^*$ ) respiratory reactance ( $\text{Xrs5}$ ) and interrupter technique ( $\text{Rint}^*$ ). All these techniques provide reliable tools for monitoring the response during bronchial challenge test with pharmacological agents. The reproducibility of the measurements and the sensitivity in detecting changes in the airway function are good and favorable, compared with standard techniques like the forced expiratory maneuver ( $\text{FEV}_1^*$ ) in small children. Small children do not have the ability to perform the  $\text{FEV}_1$  manoeuvre correctly [57,58].



(\* $\text{Rrs5}$  = Respiratory resistance (measured by oscillation technique).

$\text{Rint}$  = the interrupter technique for measuring respiratory resistance.

$\text{sRaw}$  = Whole-body plethysmography for measuring the specific airway resistance.

$\text{FEV}_1$  = forced expiratory volume in 1 second,  $\text{FEV}_1\%$  vital capacity (VC).

\* $\text{Xrs5}$  = respiratory reactance (measured by oscillation technique) (Methacolin was used as pharmacological test agent) [57,58].



23. Berkenbosch JW, Lam J, Burd RS et al. Noninvasive monitoring of carbon dioxide during mechanical ventilation in older children: End-tidal versus transcutaneous techniques *Anesth Analg (Pediatric Anesthesia)* 2001; 92: 1427-31.
28. Lundstrøm KE. Continuous blood gas monitoring in neonates and infants. Radiometer Medical ApS, Åkandevvej 21, 2700 Brønshøj, Denmark, 2005 (928-408). 200502B 1-16, ([www.tc-monitoring.com](http://www.tc-monitoring.com)).
45. Lagerkvist A-L, Sten G, Redfors S et al. Repeated blood gas monitoring in healthy children and adolescents by the transcutaneous route. *Paediatric Pulmonology* 2003; 35: 274-79.
46. Nosovitch MA, Johnson JO, Tobias JD. Noninvasive intraoperative monitoring of carbon dioxide in children; endtidal versus transcutaneous techniques. *Paediatric anaesthesia* 2002; 12: 48-52.
47. Simonds AK, Ward S, Heather S et al. Outcome of paediatric domiciliary mask ventilation in neuromuscular and skeletal disease. *Eur Respir J* 2000; 16: 476-81.
48. Berkenbosh JW, Tobias JD. Transcutaneous carbon dioxide monitoring during high-frequency oscillatory ventilation in infants and children. *Crit Care Med* 2002; 30, 5: 1024-27.
49. Nielsen LM, Halgrener J, Hansen BVL. Respiratorisk syncytialvirus-infektioner hos børn i almen praksis. *Ugeskrift for læger: Videnskab og praksis* 2003; 165,27: 2747-49.
50. Hall CB. Respiratory syncytial virus and parainfluenza virus. *N Engl J Med* 2001; 344: 1927-28.
51. Gaultier C, Praud JP, Clément A et al. Respiration during sleep in children with COPD. *Chest* 1985; 87, 2: 168-73.
52. Morielli A, Desjardins D, Brouillette RT. Transcutaneous and end-tidal carbon dioxide pressures should be measured during pediatric polysomnography. *Am Rev Respir Dis* 1993; 148, 6: 1599-1604.
53. Tobias JD, Meyer DJ. Noninvasive monitoring of carbon dioxide during respiratory failure in toddlers and infants: End-tidal versus transcutaneous carbon dioxide. *Anesth Analg* 1997; 85: 55-58.
54. Center for Disease Control Surveillance for Asthma – US, 1960-1995 MMWR. 1998; (SS-1); [http://www.AAAAI.org/media/resources/media\\_kit/asthma\\_statistics.stm](http://www.AAAAI.org/media/resources/media_kit/asthma_statistics.stm)
55. <http://www.who.int/int/respiratory/asthma/en/>
56. kilde Holmgren D, Redfors S, Wennergren G et al. Histamine provocation in young, awake children with bronchial asthma, using a fall in oxygenation as the only indicator of a bronchial reaction 1999; *Acta. Pædiatr* 88: 545-9.
57. Klug BH. Evaluation of some techniques for measurements of lung function in young children. Lægeforeningens forlag, København 2002: 1-21 (Doctor's thesis)
58. Quanjer PH et al. Become an expert in spirometry 2006. <http://www.spirx-pert.com/indices/7.htm> 59. Holmgren D; Redfors S, Solymar L. Transcutaneous- $pO_2$  monitoring for detection of exercise-induced right-to-left shunts in children with congenital heart defects: A case report. *Acta Paediatr* 2001; 90: 816-8.
59. Holmgren D; Redfors S, Solymar L. Transcutaneous- $pO_2$  monitoring for detection of exercise-induced right-to-left shunts in children with congenital heart defects: A case report. *Acta Paediatr* 2001; 90: 816-8.

## Operating room, ICU and step-down units

### Carbon dioxide in critically ill adult patients

In Intensive Care Units (ICU), it is vital to continuously monitor arterial carbon dioxide tension. This is commonly performed by analysis of arterial blood gas samples or derived from end-tidal  $p\text{CO}_2$  measurement. Arterial blood samples require an arterial puncture or insertion of a catheter with the associated risks and inconvenience for the patients. In addition blood gases are only analyzed intermittently. End-tidal  $p\text{CO}_2$  is a poor predictor of  $\text{PaCO}_2$ , as it normally underestimates  $\text{PaCO}_2$ . The relationship between the two values varies largely, depending on the ventilation-perfusion ratio and cardiac output. Thus,  $\text{tcpCO}_2$  monitoring is an alternative way of noninvasive estimation of arterial carbon dioxide tension without the drawbacks of end-tidal  $p\text{CO}_2$  [4, 21].

### $\text{tcpCO}_2/\text{PaCO}_2$ correlation studies

Many TC studies focus on the  $\text{tcpCO}_2/\text{PaCO}_2$  correlation; however, the major advantage of the  $\text{tcpCO}_2$  technique is that it is non-invasive and follows the trends of  $\text{PaCO}_2$  with less than 1 minute of delay. A number of different TC correlation studies are quoted in the following pages.

A major study tested the  $\text{tcpCO}_2/\text{PaCO}_2$  correlation in a wide range of arterial carbon dioxide tension values: 26-71 mmHg (3.4 - 9.4 kPa). The authors found a close correlation ( $r = 0.968$ ,  $p < 0.0001$ ); mean bias was 0.75 mmHg (0.1 kPa) (limits of agreement: -4.5 to +6 mmHg (0.6 to-0.8 kPa).

This study also included a review of 16 other  $\text{tcpCO}_2/\text{PaCO}_2$  correlation studies. In general, these studies showed good correlation. The authors state that some errors seemed to be

related to:

- A particular capnograph (in sleep studies)
- Lack of calibration before every measurement
- Not allowing sensor sufficient stabilization time
- Inadequate cutaneous perfusion

It was concluded that  $\text{tcpCO}_2$  in hemodynamically stable patients was in excellent agreement with  $\text{PaCO}_2$ , and that the response to change in ventilation was compatible with the aim of clinical monitoring of non-invasively mechanically ventilated patients [22].

Two recent studies found a similar correlation with an even wider range of carbon dioxide values: 21-85 mmHg (2.8-11.33 kPa) 38-165 mmHg (5-22 kPa) [60, 61].

So far no studies have evaluated normal or reference  $\text{tcpCO}_2$  values for different patient groups. This is probably because transcutaneous monitoring is a tool for monitoring carbon dioxide trends [62].

Transcutaneous carbon dioxide monitoring has shown to provide a better estimate of  $\text{PaCO}_2$  than end-tidal  $p\text{CO}_2$  during general anesthesia in patients with a body mass index greater than 40  $\text{kg/m}^2$  [63].

### Transcutaneous trends in critically ill patients

A new study focused on  $\text{tcpCO}_2$  trends in critically ill patients, which vary more than 8 mmHg (1.06 kPa) from the corresponding  $\text{PaCO}_2$  value. The purpose was to evaluate if relevant carbon dioxide changes were indicated in the  $\text{tcpCO}_2$  trend shift. A trend shift was defined as: A difference between  $\text{tcpCO}_2$  and  $\text{PaCO}_2$  that was more than 8 mmHg (1.06 kPa).

They found the following:

Sensitivity	Specificity	PPV*	NPV*
86 %	80 %	60 %	97 %

(\*Positive predictive value/negative predictive value)

The patients in the study had septic shock, cardiac arrest, cardiogenic shock and other diagnoses. It was concluded that  $\text{tcpCO}_2$  provides a safe and reliable trend-monitoring tool if there is no major vasoconstriction [24,25].

### **Sustained elevated $\text{tcpCO}_2$ in trauma patients**

High  $\text{tcpCO}_2$  values within the first hour of hospital admission were shown to correlate well with mortality in trauma patients. The patients were monitored with  $\text{tcpCO}_2$  immediately after admission. Early signs of poor tissue perfusion within the first hour could be related to survivors and non-survivors. Sustained elevated  $\text{tcpCO}_2$  levels for more than 30 minutes were associated with a 100 % mortality rate [4,64].

### **High Frequency Oscillatory Ventilation and non-invasive positive pressure ventilation**

A combined  $\text{tcpCO}_2/\text{SpO}_2$  measurement is relevant in clinical settings of non-invasive positive pressure ventilation and high-frequency oscillatory ventilation (HFOV), where end-tidal  $\text{pCO}_2$  measurement and clinical assessment can be difficult or impossible.  $\text{tcpCO}_2$  was also shown to be a useful tool for adjustment of the driving pressure in the jet ventilator for "rigid bronchoscopy patients" during high-frequency jet ventilation (HFJV). This is especially relevant in overweight patients with pulmonary diseases and during long-lasting procedures with endobronchial interventions [66,76].

Since only the proximal airway pressure is monitored during HFOV and HFJV, no alarm will occur in the event of obstruction or restriction of the airways. The technique also induces a risk of hyperventilation resulting in hypocapnia. HFOV manufacturer guidelines recommend  $tcpCO_2$  /  $tcpO_2$  and  $SpO_2$  are measured during treatment. This is particularly important in older children and adults who have more dead space and a greater metabolic demand on ventilation [42].

### **Hypercapnic respiratory failure and oxygen therapy**

A study evaluating intermittent positive pressure ventilation recommends that patients with hypercapnic respiratory failure in oxygen therapy are assessed with initial arterial blood gases and continual pulse oximetry plus  $tcpCO_2$  monitoring during sleep [67].

### **One-lung ventilation**

Various factors may influence the difference between  $PaCO_2$  and end-tidal  $pCO_2$  during thoracic anesthesia. Many thoracic surgical patients have some degree of preoperative lung dysfunction and a history of smoking. One-lung ventilation is often used to improve surgical exposure during thoracic procedures. However, one-lung ventilation impairs the ventilation/perfusion matching. Several studies have concluded that patients undergoing one-lung ventilation are significantly better monitored by  $tcpCO_2$  than by end-tidal  $pCO_2$  [68,69].



## Secondary pulmonary hypertension

Patients with COPD, obstructive sleep apnea and cystic fibrosis sometimes develop secondary pulmonary hypertension.  $\text{tcpCO}_2$  / ( $\text{tcpO}_2$ ) and  $\text{SpO}_2$  are sometimes used as part of the evaluation of the respiratory status of these patients, neonates, children as well as adults [70,71,72,73].

### Hypotensive shock diagnosed by $\text{tcpO}_2$

In one study more than 300 acute episodes of circulatory dysfunction and shock in the ICU were evaluated. It was concluded that "Non-invasive measurements identify early circulatory problems reliably and provide objective criteria for physiological analysis as well as definition of therapeutic goals and titration of therapy". Transcutaneous oxygen and carbon dioxide tensions were used to assess tissue perfusion and oxygenation. The authors refer to several studies that have documented experimentally and clinically that  $\text{tcpO}_2$  changes with alterations in oxygen metabolism. The authors found that hypotensive shock usually was preceded by episodes of high flow, which was then followed by a period of low flow and inadequate tissue perfusion. The latter was detected by a reduced  $\text{tcpO}_2$  [74].

Please note that even if transcutaneous oxygen significantly correlates with arterial values, the agreement between  $\text{tcpO}_2/\text{PaO}_2$  indicates that it should not be used as a solo estimation of  $\text{PaO}_2$  in adult patients, however as documented above it can be an early warning of a shock [20, 27].

## Conscious sedation during diagnostic surgery

### Conscious sedation

In a state of moderate or deep sedation (during diagnostic or therapeutic procedures), regular breathing will often be disturbed by moving, squeezing, coughing or changes between nose and mouth ventilation, causing leakage and therefore artifacts or misinterpretation of the data obtained with end-tidal  $p\text{CO}_2$ . These problems often restrict the use of side-stream capnography although the American Society of Anesthesiologists and the American Society of Gastrointestinal Endoscopy suggest in their guidelines that external monitoring with capnography should be considered for patients in conscious and deep sedation [60,65].

In recent years, new anesthetic drugs and advanced interventional techniques have been used increasingly. During moderate sedation, e.g. during colonoscopy, some patients may unintentionally be sedated to a level of general anesthesia. These patients may develop respiratory depression or airway obstruction. In two studies on patients undergoing colonoscopy,  $\text{SpO}_2$ ,  $\text{tcpCO}_2$  and end-tidal  $p\text{CO}_2$  were used to monitor patient status. Because of supplemental oxygen supply, the pulse oximeter did not show early signs of hypoventilation while  $\text{tcpCO}_2$  monitoring did indicate prolonged hypoventilation. It was concluded that during moderate sedation  $\text{tcpCO}_2$  monitoring might provide a better monitoring of the ventilation than end-tidal  $p\text{CO}_2$ ; however, airway obstruction was indicated earlier by end-tidal  $p\text{CO}_2$  [60,65].

### Bronchoscopy and COPD exacerbation

Studies have shown that  $\text{tcpCO}_2$  often increases while patients are on assisted ventilation during bronchoscopy. Monitoring  $\text{tcpCO}_2$  assists ventilator adjustments, and is very helpful in assessing patients during the initial periods off the ventilator. The

authors further states that trending carbon dioxide levels is also relevant in patients with COPD exacerbation [75,76].

### Endoscopy

A randomized, controlled trial evaluated the ability to detect carbon dioxide retention purely by clinical observation or pulse oximetry in patients receiving supplemental oxygen. 395 patients were followed with these two methods and with  $\text{tcpCO}_2$  during Endoscopic Retrograde Cholangiopancreatography (ERCP). Neither clinical observation nor the  $\text{SpO}_2$  surveillance technique reliably detected carbon dioxide retention. It was concluded that additional  $\text{tcpCO}_2$  monitoring prevented severe carbon dioxide retention more effectively. In 10 % of the patients who received supplemental oxygen,  $\text{SpO}_2$  did not indicate desaturation even though  $\text{tcpCO}_2$  increased by more than 20 mmHg. Furthermore,  $\text{tcpCO}_2$  monitoring facilitates a slightly deeper mean sedation and a significantly shorter duration of inadequate sedation. The overall doses of sedative and analgesic drugs were the same irrespective of the chosen surveillance technique. This indicated that transcutaneous carbon dioxide tension monitoring provided a more precise titration and timing of these drugs during ERCP [77].





61. Cox M, Kemp R, Anwar S. *et al.* Non-invasive monitoring of CO<sub>2</sub> levels in patients using NIV for AECOPD. *Thorax* 2006; 61: 363-4.
62. Nelson DB, Freeman ML, Silvis SE *et al.* A randomized, controlled trial of transcutaneous carbon dioxide during ERCP. *Gastrointestinal endoscopy* 2000; 51, 3: 288-95.
63. Griffin J, Terry BE, Burton RK *et al.* Comparison of end-tidal and transcutaneous measures of carbon dioxide during general anaesthesia in severely obese adult. *Br J Anaesth* 2003; 91, 4: 498-501.
64. Tatevassian RWC. Transcutaneous oxygen and CO<sub>2</sub> as early warning of tissue hypoxia and homodynamic shock in critically ill emergency patients; 2000; *Crit Care med*; 28(7): 2248-53.
65. Brown BJ, Richardson C, Ellis-Stoll C *et al.* Transcutaneous CO<sub>2</sub> monitoring versus end tidal CO<sub>2</sub> during Propofol sedation. Poster present at the annual ASA meeting (October 2006).
66. Männle C, Herth FJ, Becker HD *et al.* Controlling of high frequency jet ventilation by measurement of the Transcutaneous carbon dioxide tension (tcpCO<sub>2</sub>) during rigid bronchoscopy. *Chest* 2003, 124, 4: 125S
67. Sivasothy P, Smith IE, Shneerson JM. Mask intermittent positive pressure ventilation in chronic hypercapnic respiratory failure due to chronic obstructive pulmonary disease. *Eur Respir J* 1998; 11: 34-40.
68. Tobias JD. Noninvasive carbon dioxide monitoring during one-lung ventilation: End-tidal versus transcutaneous techniques. *Journal of Cardiothoracic and Vascular Anesthesia* 2003; 17, 3: 306-08.
69. Oshibuchi M, Cho S, Hara T *et al.* A comparative evaluation of transcutaneous and end-tidal measurements of CO<sub>2</sub> in thoracic anesthesia. *Anesth analg* 2003; 97: 776-79
70. Petersen JR, Galløe AM, Graudal NA. Intet grundlag for behandling af pulmonal hypertension med vasodilatation. *Ugeskr Læger* 1994; 156, 15: 2219-26.
71. Franker KL, Tullis E, Sasson Z *et al.* Pulmonary hypertension and cardiac function in adult cystic fibrosis. *Chest* 1999; 115: 1321-28.
72. Alswang M, Friesen RH, Bangert P. Effect of preanesthetic medication on carbon dioxide tension in children with congenital heart disease. *J Cardiothorac Vasc Anaesth* 1994; 8, 4: 415-19.
73. Zin W Y. Clinical study on hemodynamics, blood gases and hemorheologic monitoring of patients with cor pulmonale. *Zhong xi yi jie he za zhi* 1989; 9, 9: 522-14.
74. Shoemaker WC, Wo CCJ, Demetriades D *et al.* Scientific reviews: Early physiologic patterns in acute illness and accidents: Toward a concept of circulatory dysfunction and shock based on invasive and noninvasive hemodynamic monitoring. *New Horizons* 1996; 4, 4: 395-12.
75. Dalbec R, Batool S, Levin Y *et al.* Transcutaneous pCO<sub>2</sub> monitoring in a ventilator weaning unit. AARC 51st International Respiratory Congress, Program from the open forum no. 1. 2005; OF-05-116: 70.
76. Rowley D, Walsh BK, Young BS *et al.* Evaluation of a new digital transcutaneous tcpCO<sub>2</sub> & SpO<sub>2</sub> combination sensor and its correlation to ABG PaCO<sub>2</sub>. AARC 51st International Respiratory Congress, Program from the open forum no. 1. 2005; OF-05-106: 69.
77. Evans EN, Ganeshalingam K, Ebdon P. Changes in oxygen saturation and transcutaneous carbon dioxide levels in patients undergoing fiberoptic bronchoscopy. *Respiratory Medicine* 1998, 92: 739-42

## Pulmonary/respiratory medicine laboratory or wards

### COPD

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of respiratory morbidity, The European Commission for Public Health characterizes COPD as a leading cause of chronic morbidity and the US National Institutes of Health list it as the fourth-leading cause of death in the US [78].


COPD patients are often old and hospitalized repeatedly for longer or shorter periods of time, and it is therefore important to minimize the interventions and use non-invasive surveillance. Monitoring of the carbon dioxide tension level by a combined  $\text{tcpCO}_2/\text{SpO}_2$  probe is, according to the studies mentioned below, often the right choice.

### Carbon dioxide monitoring in COPD and other respiratory patients

A study compared  $\text{PaCO}_2$  with arterialized capillary blood ( $\text{PacCO}_2$ ),  $\text{tcpCO}_2$ , end-tidal  $p\text{CO}_2$  and physiological respiratory dead space-to-tidal volume ( $\text{VD}/\text{VT}$ ) ratio in COPD patients, postoperative cardiac surgery patients and healthy control subjects. Patients were evaluated at three mechanical ventilator patterns.  $\text{PaCO}_2$ ,  $\text{tcpCO}_2$ , end-tidal  $p\text{CO}_2$  correlated well with  $\text{VD}/\text{VT}$  and  $\text{PaCO}_2$  (0.99, 0.97 and 0.87). However, other studies have demonstrated that end-tidal  $p\text{CO}_2$  is inaccurate in patients with ventilation/perfusion mismatch [21,27,79].

### COPD exacerbation during oxygen therapy

Hypoxic patients with acute exacerbation of COPD are, according to studies and the guideline “The ABC of oxygen therapy”, at risk of carbon dioxide retention when they receive oxygen therapy. A combined  $tcpCO_2$ / $SpO_2$  measurement has shown to be useful in clinical settings of non-invasive positive pressure ventilation, where end-tidal  $pCO_2$  measurement and clinical assessment can be difficult. In Fig. 9, an example of monitoring of a COPD patient is shown [76,80].



**FIG. 9: COPD patient during high-flow oxygen in sufflation.**

A COPD patient, monitored by continuous  $tcpCO_2$ / $SpO_2$  and pulse rate, during delivery of a transtracheal high-flow oxygen insufflation. The ventilation was measured by means of a respiratory inductive plethysmograph ( $V_t$  = change of lung volume). [81].

## Ventilator manipulation according to $tcpCO_2$


A study found  $tcpCO_2$  measurements was appropriate for estimating the ventilatory response to Non-Invasive Ventilation (NIV) in patients with hypercapnic ventilatory failure due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD) [61].

## Nocturnal oxygen desaturation in patients with COPD

Nearly 80 % of patients with severe chronic COPD experience nocturnal oxygen desaturation due to hypoventilation. The consequence is an increased arterial carbon dioxide tension, and it may result in nocturnal and daytime symptoms of respiratory failure, cor pulmonale, etc. These patients might benefit from  $tcpCO_2$  monitoring during the night, when started on oxygen therapy.

Continuous non-invasive assessment of carbon dioxide tension is crucial in the sleep lab for diagnosis and treatment of patients with severe COPD. A study has shown a strong correlation between daytime levels of  $PaCO_2$  and the severity of hypoventilation during the night, i.e. high daytime levels of carbon dioxide are more likely to lead to hypercapnia during the following night. A similar relationship between night- and daytime hypoventilation was seen in a randomized, controlled multicenter trial, where many patients' hypercapnia was detected by a  $tcpCO_2$  measurement. This study documents that stable COPD patients' daytime  $PaCO_2$  levels can be improved by  $tcpCO_2$  - based adjustments of the nocturnal non-invasive ventilation. An example of a patient measurement from this study is shown in figure 10 [67,78,82].





**FIG. 10: A nocturnal patient measurement**

a) Sample hypnogram showing the patients' stage of sleep.

b) Nocturnal tcpCO<sub>2</sub> recordings. Note the correlation between an elevated tcpCO<sub>2</sub> and REM (rapid eye movement) sleep. The time is indicated on the x-axis in periods of 30 sec duration. The closed arrow shows episode 55 (tcpCO<sub>2</sub>: 6.61 kPa (49.7 mmHg) and PaCO<sub>2</sub>: 6.29 kPa (47.3 mmHg)); Open arrow indicates episode 923 (tcpCO<sub>2</sub>: 8.09 kPa (60.8 mmHg) and PaCO<sub>2</sub>: 7.39 kPa (55.6 mmHg)). "—" = tcpCO<sub>2</sub> with in vivo calibration and "....." = tcpCO<sub>2</sub> without in vivo calibration. (Copyright obtained from Eur Respir J) [78]

## Acute Respiratory Distress Syndrome (ARDS)

In a study on patients with various respiratory conditions it was concluded that tcpCO<sub>2</sub> provides a better indication of ventilation status than end-tidal pCO<sub>2</sub>. The authors write that this is due to an increased dead space ventilation or ventilation in excess of perfusion. Under these circumstances (high V/Q mismatch) the carbon dioxide may be inadequately removed from the bloodstream and the PaCO<sub>2</sub> will increase without an equivalent increase in the end-tidal pCO<sub>2</sub>. The discrepancy be-

tween arterial and end-tidal  $p\text{CO}_2$  is particularly large in ARDS patients [83].

### **Non-invasive ventilation**

Increasing evidence of the benefits of Non-invasive Positive Pressure Ventilation (NPPV) in a variety of pulmonary disorders has led to its widespread use.  $\text{tcpCO}_2$  was shown to be in excellent agreement with  $\text{PaCO}_2$  in hemodynamically stable adults. Also the time for a change in ventilation to be detected by  $\text{tcpCO}_2$  measurements was shown to be compatible with the aim of clinical monitoring of patients under NPPV [22].

### **Leaks during non-invasive positive pressure ventilation**

It has been documented that many non-invasively ventilated patients have clinically relevant mouth or other air leaks, and this should therefore be measured routinely. The leaks are especially seen if nasal resistance is high, if treatment is not optimum or if sleep architecture appears to be impaired. A study on awake control subjects has confirmed that a large mouth leak is very distressing and is a likely cause of severe sleep disruption. Sleeping patients with a mouth leak during nasal bi-level ventilatory assistance have been found to have an increased  $\text{tcpCO}_2$  [84].

### **One-lung ventilation**

Several studies have shown that transcutaneous monitoring of carbon dioxide tension provides a more accurate estimation of the  $\text{PaCO}_2$  during one-lung ventilation (OLV) than end-tidal  $p\text{CO}_2$  measurements. The table below, taken from one of these studies shows a significantly larger difference between the end-tidal  $p\text{CO}_2$  and  $\text{PaCO}_2$  compared with the difference between the  $\text{tcpCO}_2$  and  $\text{PaCO}_2$  in patients with 1 hour of OLV during thoracic anesthesia.

Time	Difference in mmHg relative to PaCO <sub>2</sub>	
Minutes of OLV	End-tidal pCO <sub>2</sub>	tcpCO <sub>2</sub>
15	6.1 ± 4.6 *	0.0 ± 2.5
30	5.3 ± 4.1 *	0.0 ± 2.4
45	5.5 ± 3.7 *	0.2 ± 2.3
60	6.3 ± 4.1 *	1.3 ± 2.6

The values are expressed as difference ± SD (\* significant difference P < 0.05) [72].

This study also found this significant difference in the two-lung ventilation technique: end-tidal pCO<sub>2</sub> – PaCO<sub>2</sub>: -7.1 ± 4.6 mmHg versus tcpCO<sub>2</sub> – PaCO<sub>2</sub>: 1.4 ± 4.3 mmHg [68,69].

### Respiratory testing

For asthma patients, some doctors find that measurement of non-specific bronchial hyperreactivity caused by inhaled bronchoconstrictor agents provides important research and diagnostic aid.

tcpCO<sub>2</sub> monitoring has proven to provide a useful and reliable tool for analysis of the slope of dose-response curves to inhaled methacholine in asthmatic adult patients [85,86].

### Notes

---

---

---

---

---

---

---

---

---

---

21. Bendjelid K, Schütz N, Stotz M *et al.* Transcutaneous  $p\text{CO}_2$  monitoring in critically ill adults: Clinical evaluation of a new sensor. *Crit Care Med* 2005; 33, 10: 2203-06.
22. Janssens J-P, Howarth-Frey C, Chevrolet J-C *et al.* Transcutaneous  $p\text{CO}_2$  to monitor noninvasive mechanical ventilation in adults: Assessment to a new transcutaneous  $p\text{CO}_2$  device. *Chest* 1998; 113: 768-73.
27. Janssens J-A, Laszlo A, Uldry C *et al.* Non-invasive (transcutaneous) monitoring of  $p\text{CO}_2$  ( $\text{tcpCO}_2$ ) in older adults. *Gerontology* 2005; 51: 174-78.
36. Wilson J, Russo P, Russo JA *et al.* Noninvasive monitoring of carbon dioxide in infants and children with congenital heart disease: End-tidal versus transcutaneous techniques. *J Intensive Care Med* 2005; 20, 5: 291-95.
61. Cox M, Kemp R, Anwar S. *et al.* Non-invasive monitoring of  $\text{CO}_2$  levels in patients using NIV for AECOPD. *Thorax* 2006; 61: 363-64.
67. Sivasothy P, Smith IE, Shneerson JM. Mask intermittent positive pressure ventilation in chronic hypercapnic respiratory failure due to chronic obstructive pulmonary disease. *Eur Respir J* 1998; 11: 34-40.
68. Tobias JD. Noninvasive carbon dioxide monitoring during one-lung ventilation: End-tidal versus transcutaneous techniques. *Journal of Cardiothoracic and vascular Anesthesia*. 2003; 17, 3: 306-08.
69. Oshibuchi M, Cho S, Hara T *et al.* A comparative evaluation of transcutaneous and end-tidal measurements of  $\text{CO}_2$  in thoracic anesthesia. *Anesth analg* 2003; 97: 776-79.
76. Rowley D, Walsh BK, Young BS *et al.* Evaluation of a new digital transcutaneous  $\text{tcpCO}_2$  &  $\text{SpO}_2$  combination sensor and its correlation to ABG  $\text{PaCO}_2$ . AARC 51st International Respiratory Congress, Program from the open forum no. 1. 2005; OF-05-106: 69.
77. Chaouat A, Weitzenblum E, Krieger J *et al.* Association of chronic obstructive pulmonary disease and sleep apnea syndrome. *Am J Respir Crit Care Med* 1995; 151,1: 82-86
78. O'Donoghue FJ, Catcheside PG, Ellis EE *et al.* Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: Prevalence and associated factors; *Eur Respir J* 2003; 21: 977-84.
79. Xie X-B; Liu Y. Application of bedside monitoring with arterized capillary blood, transcutaneous and end tidal carbon dioxide during mechanical ventilation. *Zhonghua jie he he hu xi za zhi* = *Zhonghua jiehe he huxi zazhi* (= Chinese Journal of tuberculosis and respiratory diseases) 1993; 16, 2: 98-100 (English abstract 124-5).
80. Bateman NT, Leach RM. Clinical review. ABC of oxygen. Acute oxygen therapy. *BMJ* 1998; 317. 798-801.
81. Brack T, Senn O, Russi EW, Bloch KE. Transtracheal high-flow insufflation supports spontaneous respiration in chronic respiratory failure. *Chest* 2005; 127: 1: 98-04. Reprinted in Tosca - Selected case reports. Adipositas-hypoventilation syndrome. 2005; Patient 1: Figure 2: 5. (Linde Medical Sensors AG, Austrasse 25, Ch-4051, Basel, Switzerland)
82. Jennum PJ, Tønnesen P, Rasmussen N *et al.* Søvnrørelser, definition, forekomst, patofysiologi og konsekvenser. *Ugeskr Læger* 2005; 167, 22: 2380-85.
83. Blanchette T, Dziodzio J. Transcutaneous  $p\text{CO}_2$  and end-tidal  $p\text{CO}_2$  in ventilated adults. *Respiratory Care* 1992; 92, 3: 240-47.
84. Teschler H, Stampa J, Ragette R *et al.* Effect of mouth leak on effectiveness of nasal bilevel ventilatory assistance and sleep architecture. *Eur Respir J* 1999; 14: 1251-57.

85. Fontana GA, Lavorini F, Boddi V *et al.* Comparison of dose-response slopes obtained by simultaneous assessment of changes in FEV1 and transcutaneous oxygen partial pressure during methacholine challenges in asthmatic patients. *Journal of Asthma* 1995; 32, 4: 301-407
86. Fontana GA, Cardellicchio S, Camiciottoli G *et al.* Changes in transcutaneous oxygen partial pressure as an index of response to inhaled methacholine in asthmatic patients. *Chest* 1993; 103,5: 1375-80.

## Sleep laboratories


### Sleep apnea

Sleep apnea affects people worldwide. According to a WHO estimations 5-20 million people in Europe and 15-20 million in the US are affected by this disease and 11 % of the US obstructive sleep apnea patients also have COPD. If untreated, these patients suffer from excessive daytime sleepiness and impaired cognitive performance. There is also an increased risk of causing traffic accidents and suffering from cardiovascular diseases. Continuous non-invasive monitoring of the  $\text{SpO}_2$  levels and trends have proven to be crucial in the sleep laboratory for diagnosis and treatment of these patients. Correspondingly,  $\text{tcpCO}_2$  monitoring is useful to detect hypoventilation [76,77, 78].



### Episodes of hypoventilation

In order to avoid potentially dangerous hypoventilation or suboptimum nocturnal ventilatory assistance, a combined  $\text{tcpCO}_2/\text{SpO}_2$  measurement is useful in clinical settings using non-invasive positive pressure ventilation. Episodes of hypoventilation lasting as little as 30 seconds were detectable by the  $\text{tcpCO}_2$  monitoring [76,78].



**FIG. 11: Nocturnal recording**

An example of nocturnal recording in a patient with obesity-hypoventilation and sleep apnea syndrome. Recordings were done between 6 pm and 6 am with a combined  $\text{tcpCO}_2/\text{SpO}_2$  earlobe sensor. The arrows illustrate how well  $\text{SpO}_2$ ,  $\text{tcpCO}_2$  and the pulse rate reflects events of hypoventilation and resumption of normal ventilation, respectively [81].

## Cystic fibrosis

Patients with advanced cystic fibrosis may develop hypoxia and hypercapnia during sleep, particularly during REM sleep. Elevated evening levels of  $\text{PaCO}_2$  were found to be associated with both sleep-related desaturation and the rise in  $\text{tcpCO}_2$  in periods of NREM-to-REM sleep in these patients [88].

## Patients undergoing long-term non-invasive ventilation

Long-term nocturnal non-invasive ventilation improves day-time symptoms of hypoventilation, sleep quality and respiratory failure even when patients are not on ventilatory support.  $\text{tcpCO}_2$  monitoring is an important tool to evaluate effectiveness of treatment and adjust ventilator settings [89].

## Leaks in ventilation

As mentioned in the section on pulmonary medicine, patients on noninvasive positive pressure ventilation often have leaks from the mask or through the mouth. This may disturb the sleep architecture. The associated increases in the carbon dioxide level can be detected by  $\text{tcpCO}_2$  monitoring [82].

## Notes



76. Rowley D, Walsh BK, Young BS *et al.* Evaluation of a new digital transcutaneous  $\text{tcpCO}_2$  &  $\text{SpO}_2$  combination sensor and its correlation to ABG  $\text{PaCO}_2$ . AARC 51st International Respiratory Congress, Program from the open forum no. 1. 2005; OF-05-106: 69.
77. Chaouat A, Weitzenblum E, Krieger J *et al.* Association of chronic obstructive pulmonary disease and sleep apnea syndrome. *Am J Respir Crit Care Med* 1995; 151, 1: 82–86.
78. O'Donoghue FJ, Chatcheside PG, Ellis EE *et al.* Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: Prevalence and associated factors; *Eur Respir J* 2003; 21: 977–84.
81. Bloch KE. Tosca - Selected case reports. Adipositas-hypoventilation syndrome. 2005; Patient 1: figure 2: 5. (Linde Medical Sensors AG, Austrasse 25, Ch-4051, Basel, Switzerland)
82. Teschler H, Stampa J, Ragette R *et al.* Effect of mouth leak on effectiveness of nasal bilevel ventilatory assistance and sleep architecture. *Eur Respir J* 1999; 14: 1251-57.
86. Mullory E, McNicholas WT. Ventilation and gas exchange during sleep and exercise in severe COPD. *Chest* 1996; 109, 2: 387-94.
88. Milross MA, Piper AJ, Norman M *et al.* Predicting sleep-disordered breathing in patients with cystic fibrosis. *Chest* 2001; 120: 1239-45.
89. Piper AJ, Sullivan CE. Effect of long-term nocturnal nasal ventilation on spontaneous breathing during sleep in neuromuscular and chest wall disorders. *Eur Respir J* 1996; 9: 1515-22.

## Veterinary hospitals/laboratories

### Animals

Although transcutaneous monitoring was originally developed for human use, the literature has shown several examples of its use on animals. Before TC measurement it is necessary to prepare the skin, in order to optimize the conditions for carbon dioxide and oxygen diffusion through the skin. Removing the hair and the upper layer of dead skin cells is therefore advised. Do not use any kind of chemicals for hair removal, as they will affect the measurements. On larger animals like pigs, some authors recommend that the relevant skin area is carefully rubbed with sand paper to prepare the skin for the measurement (after the hair has been removed) [90].

### **tcpCO<sub>2</sub> - PaCO<sub>2</sub> correlation in mice and rats**

A linear relationship between tcpCO<sub>2</sub> and PaCO<sub>2</sub> was seen in mice and different races of rat [91].

### **Skin viability in dogs**

A study concludes that transcutaneous oxygen is useful for assessing skin viability in dogs [92].

### **Hemorrhagic shock in pigs**

Twelve-week-old pigs were used for evaluating the severity of hemorrhagic shock. Together with measuring pH in the intramucosal wall, transcutaneous monitoring of oxygen indicated blood volume loss more rapidly than, for example cardiac output [90].

### **Not all animal studies show good results**

Some animal studies have shown suboptimum results. This may be due to improper preparation of the animal's skin, or limitations of the TC technique. It is therefore recommended to conduct a validation of the measurements before new kinds of animal studies or clinical uses are initiated.

## Experimental use of the TC technique

Experimental use of the TC technique sometimes requires new ways of thinking. An example of this is an unpublished case story based on TC intestinal oxygen measurement in a horse undergoing ileus surgery. As the intestine is wet and moving, it is impossible to use fixation rings for attaching the sensor during surgery. The veterinarians used a clean (but not sterilized) tcpO<sub>2</sub> sensor with a new membrane. They used a sterile glove, where they cut a hole for the head of the sensor, so the sensor could be placed directly on the moving intestine without contact gel or liquid. The measuring temperature was low to avoid burns. This method enabled them to decide where the tissue had sufficient levels of oxygen and where the oxygenation was too low. The operation went well; afterwards the horse was treated with antibiotics, and it did not show any signs of infection [\*].

\* Not published material.

## Notes

90. Hartmann M, Montgomery A, Jönsson K et al. Tissue oxygenation in hemorrhagic shock measured as transcutaneous oxygen tension, subcutaneous oxygen tension, and gastrointestinal intramucosal pH in pigs. *Critical care Medicine* 1991; 19,2: 205-10.
91. Ramos-Cabrer P, Weber R, Wiedermann D et al. Continuous noninvasive monitoring of transcutaneous blood gases for a stable and persistent BOLD contrast in fMRI studies in the rat. *NMR in Biomed* 2005; 18: 440-46.
92. Rocbat MC, Pope ER, Payne JT et al. Transcutaneous oxygen monitoring for predicting skin viability in dogs. *Am J Vet Res* 1993; 53, 3: 468-75.

# Use of the TCM4/40/ TOSCA/CombiM monitors


## **A short overview of TCM4/40/TOSCA/CombiM monitors**

This section of the handbook gives a short overview of how to work with the TCM4/40/TOSCA/CombiM monitors. For further information, please refer to the “*operator’s manual*” for these monitors.

## **Measurements**

During monitoring, the results can be viewed as current numeric results, curves, and trend tables. The monitor stores data up to 48 hours of monitoring data. It is possible to print out the data or send it to an external computer.

# Menu structure of the TCM4/40/ TOSCA/CombiM monitors



**Fig. 12: Menu structure of the TCM4/40/TOSCA/CombiM monitors**

**\*Only on the TCM TOSCA/CombiM monitors**


## Short-form support for the TCM4/40/ TOSCA/CombiM monitors



Please consult the “operator’s manuals” for instructions.

This short-form support provides only a brief overview when using the device please consult “operator’s manuals”

**Applicable for** The following short-form instructions are valid for monitors with base unit model 391-876 or later.

**Start-up** Turn on the power supply on the rear of the monitor and then press the  button on the front of the monitor.

**Shutdown** Press the  button on the front of the monitor. Then press **OK** on the screen.

*Note:* If the power switch on the rear is ON, the battery will be recharged when needed.

**Calibration** Insert the sensor in the calibration chamber and press **Calibrate**.

*Note:* Make sure the sensor is placed correctly in the chamber and that the arm is positioned horizontally across the sensor.

**SmartCal** The SmartCal function makes sure the monitor is always ready for monitoring by calibrating when needed.

Follow these steps to enable/disable SmartCal:

1. Press **Setup** → **Calibration** → **SmartCal**.
2. Use the blue arrow key to select the "SmartCal ON/OFF" option.
3. Use the black arrow keys to set the option to ON or OFF.
4. Use the blue arrow key to select the "SmartCal duration" option.
5. Use the black arrow keys to select the duration of the SmartCal period.
6. Press **OK**.

*Note:* Although the option is enabled, it is necessary to press Calibrate to start a new SmartCal period.

*Note:* If SmartCal is not activated, the monitor is calibrated manually by pressing Calibrate.

#### SmartHeat

The SmartHeat TCM4/40 function increases the sensor temperature by 1 °C (1.8 °F) NB. max. temp. 45 °C in a period of five minutes after the sensor has been removed from the calibration chamber. As a result, the  $\text{tcpO}_2/\text{tcpCO}_2$  values can be read within 8-12 minutes after sensor placement on the patient. Follow these steps to enable/disable SmartHeat:

1. Press **Setup** → **Parameter** → **pCO<sub>2</sub>** or **pO<sub>2</sub>**.
2. Use the blue arrow key to select the "SmartHeat" option.
3. Use the black arrow keys to set the option to ON or OFF.
4. Press **OK**.

*Note:* The setting of this option is common to **pCO<sub>2</sub>** and **pO<sub>2</sub>**.



Adjustment of  $p\text{CO}_2$  and  $p\text{O}_2$  alarm limits

1. Press **Setup** → **Parameter** →  **$p\text{CO}_2$**  or  **$p\text{O}_2$** .  
(Alternatively just Press on the required Parameter)
2. Use the blue arrow key to select the "Alarm high/low" options.
3. Use the black arrow keys to adjust the values.
4. Press **OK**.

Adjustment of  $\text{SpO}_2$  and pulse alarm limits

1. Press **Setup** → **Parameter** →  **$\text{SpO}_2$ /Pulse**.  
(Alternatively just press **Parameter**)
2. Use the blue arrow key to select the  $\text{SpO}_2$  alarm high/low" and "Pulse alarm high/low" options.
3. Use the black arrow keys to adjust the values.
4. Press **OK**.

Settings for SatSeconds\*

1. Press **Setup** → **Parameter** →  **$\text{SpO}_2$ /Pulse for TCM40**.
2. Use the blue arrow key to select the "SatSeconds" option.
3. Use the black arrow keys to adjust the value.
4. Press **OK**.

For a description of the SatSeconds function, see the TCM4/40 "operator's manual".

Silencing of alarm for all parameters


Press **Alarm silence** to silence the alarm for 2 minutes.


Follow these steps to disable the alarm continuously:

1. Press **Setup** → **Parameter** →  **$p\text{CO}_2$**  or  **$p\text{O}_2$**  or  **$\text{SpO}_2$ /Pulse**.

2. Use the blue arrow key to select the " $p\text{CO}_2$  -", " $p\text{O}_2$  -", " $\text{SpO}_2$  -" or "Pulse alarm" option.
3. Use the black arrow keys to set the option to ON or OFF.
4. Press **OK**.

**Alarm symbols** The alarm symbols in Normal view have the following meanings:

Alarm is off 

Alarm is on 

**Site time** The site timer is typically activated when the sensor is affixed to the patient. The site time function can be used to indicate that the sensor must be moved to another site, that medication should be given or that a monitoring period is finished. The site timer will count down to zero at 1 minute intervals, and when it reaches zero, the message "Site time end" will be displayed on the screen.

Follow these steps to adjust the Site time:

1. Press **Setup** → **Parameter** →  $p\text{CO}_2$  or  $p\text{O}_2$ .
2. Use the blue arrow key to select the "Site time" option.
3. Use the black arrow keys to set the timer.
4. Press **OK**.





**Note:** If Site time heat is set to OFF in the setup, the sensor heat is switched off when the site timer reaches zero and the TCM4/40 monitors stops monitoring; if set to ON, the heat continues.

**Note:** The setting of this option is common to  $p\text{CO}_2$  and  $p\text{O}_2$ .

Marking of event	Press <b>Event</b> → <b>OK</b> to mark an event (for instance when giving medicine). The event number will be added in the Normal, Trend table and Trend curve views.
Views	<p>In order to view the desired data format on the monitor, press <b>Setup</b> → <b>Normal</b> or <b>Trend table</b> or <b>Trend curve</b> → <b>OK</b>.</p> <p>In Trend table view, current values as well as historical values are presented. In Trend curve view, the high and low values of the ranges can be changed with the arrow keys next to the actual parameter.</p>
Cursor in Trend curve view	<p>In Trend curve view, press <b>Cursor</b> to add a cursor to the screen.</p> <p>The cursor values (<math>p\text{CO}_2</math>, <math>p\text{O}_2</math>, Power, <math>\text{SpO}_2</math>, Pulse, Time and Date) are shown in the lower right part of the screen, whereas current values are shown in the upper right part of the screen. When the cursor is moved all the way to the left, the time axis changes and it is possible to go back in time.</p>
Gas status	When there is 10 % or less gas left in the gas cylinder, the present gas level is shown in a bar during calibration. It is recommended to change the gas cylinder when the bar appears.
Change of	<ol style="list-style-type: none"> <li>1. Unscrew the old gas cylinder by turning it gas cylinder counter clockwise.</li> <li>2. Remove the white protection cap on the new gas cylinder and screw the new gas cylinder clockwise as far as possible into the socket.</li> </ol>

## Battery

If the monitor is running on battery, the remaining power is indicated at the top of the screen by the following symbols:

full , almost full ,  
low  and critically low .

## Alarm sound level

1. Press **Setup** → **Parameter** → **pCO<sub>2</sub>** or **pO<sub>2</sub>** or **SpO<sub>2</sub>/Pulse**.
2. Use the blue arrow key to select the "Alarm sound level" option.
3. Use the black arrow keys to adjust the volume.
4. Press **OK**.

*Note:* The setting of this option is common to pCO<sub>2</sub>, pO<sub>2</sub> and SpO<sub>2</sub>.

## Adjustment of date/time

1. Press **Setup** → **Technical** (enter password "19100") → **Enter** → **Date/time**
2. Adjust the date and time.
3. Press **OK**.

## Change units between kPa and mmHg.

1. Press **Setup** → **Technical** (enter password "19100") → **Enter** → **Units pCO<sub>2</sub>/pO<sub>2</sub> kPa/mmHg**
2. Adjust the units.
3. Press **OK**.

## Adjustment of default values

Adjust the default values – e.g. the unit (kPa/mmHg), the alarm limits, the curve ranges and the temperature – in order to match your local needs.

*Note:* Under technical setting it is possible to choose standard values. By pressing this button many of your settings (parameter limits, measuring time, curve view, etc.) can be changed! For complete instructions, see the operator's manual or play the tutorials in the monitor.

### Conversion factors

$$1 \text{ mmHg} = 1 \text{ Torr} = 0.133322 \text{ kPa [93]}$$

## How to apply tc sensors

### Sensors in fixation rings

1. Calibrate the tc sensor.
2. It is recommended to clean the selected measuring site with alcohol or other skin-preparation solution and, if necessary, shave the area. This will help the ring to stick better to the skin or prevent air from leaking into the fixation ring.
3. Dry the site well.
4. Take a fixation ring.
5. Remove the fixation ring from the protective film.
6. Apply the fixation ring to the measuring site as follows:
  - Press the center of the fixation ring onto the measuring site with a finger
  - Run a finger around the rim circumference

*Note:* It is important to press firmly to avoid introduction of atmospheric air under the fixation ring. Because of the difference between physiological  $tcpO_2$  and  $tcpCO_2$  and atmospheric concentrations of 20.93 %  $O_2$  and 0.03 %  $CO_2$  (\*), the  $tcpO_2/tcpCO_2$  values are easy to differentiate.

7. Fill the well in the fixation ring with 3-5 drops of the contact liquid or one drop of contact gel.
8. Affix the sensor into the fixation ring by aligning the arrow on the sensor with one of the marks on the fixation ring. Turn the sensor 90° clockwise to fasten it in the fixation ring (E5250-E5480), or click in the sensor (54-TOSCA92).

Wait for a stable reading after the sensor has been affixed to the patient.


By choosing SmartHeat on the TCM4/40 monitors, the physiological stabilization time will fall to 5-16 minutes for the  $tcpO_2$  and to 3-6 minutes for the  $tcpCO_2$ .

(\*At sea level and at a pressure of 1 atmosphere)


## How to place the ear clips and earlobe sensors




1. Clean the ear lobe with alcohol swab.




2. Take an attachment clip and remove the white cover.




3. Attach the clip to the fleshy part of the ear lobe (with the retainer ring pointing outwards). Squeeze gently to ensure that the adhesive area sticks firmly to the ear lobe. Make sure that no air is under the adhesive area.



4. Apply two drops of contact gel to the visible skin area in the center of the retainer ring; just enough to slightly wet it.



5. Remove the sensor from the calibration chamber and insert it into the retainer ring of the clip. Press slightly until it snaps in.



6. Twist the sensor into the best position. Make sure that the sensor cable is loose and will not be stretched during monitoring. Route the sensor cable properly to avoid strangulation. To ensure proper fixation of the sensor, twist the sensor carefully a quarter of a turn.



# Calibration

## When to calibrate

Radiometer recommends performing a calibration on the TCM4/40 monitors:

- prior to each monitoring period
- when changing measuring sites
- every 4 hours (TCM4/40\*) or every 8-12 hours (TCM/TOSCA/CombiM\*)
- every time an sensor has been remembraned

After a membrane change and after the TC monitor is switched on, it is recommended to calibrate the sensor twice, with a 30 minute break between the two calibrations, before a new measurement. This will minimize the sensor drift.

## In vivo calibration

*In vivo* calibration is an adjustment of the initial  $\text{tcpCO}_2/\text{tcpO}_2$  values to the initial arterial blood gas values. This is done by moving the shown TC values up or down to the initial measured  $\text{PaO}_2/\text{CO}_2$  levels. In order to perform an *in vivo* calibration, it must be selected in the setup. Draw an arterial blood gas sample at the beginning of a stable TC monitoring period and press the blood gas button. When the sample has been analyzed on a blood gas analyzer, the measured blood gas values must be typed into the TC monitor.

\*) In a study of 8 hours of continuous monitoring of  $\text{tcpCO}_2$  with this TC sensor the author concludes that the measurements gave reliable results during the 8 hours without any significant drift. In this study they changed the membrane every 48 hours. Therefore this is a possibility but this is however, not according to the above recommendations for that sensor. As an alternative one could also use the TCM/TOSCA/CombiM sensors that only has to be calibrated every 8-12 hours. [94]

In the literature there have been discussions about the need for *in vivo* calibration. In patients with severe head and brain injury, the increase in PaCO<sub>2</sub> level may lead to increased cerebral blood flow and augmenting brain edema. In these patients one author recommends performing an *in vivo* calibration at the beginning of the monitoring period and stresses the need to check it regularly. (However, other authors prefer not to use *in vivo* calibration when they work with tcpCO<sub>2</sub> monitoring.)

The study only had 12 COPD patients enrolled. The authors concluded: “tcpCO<sub>2</sub> values and variations accurately reflected PaCO<sub>2</sub> values and that this seems to be restricted to patients with PaCO<sub>2</sub> values below 56 mmHg”. However, the study only had one patient with PaCO<sub>2</sub> readings up to 56 mmHg, which makes this part of the conclusion questionable. This might also be the reason why this limited correlation was not confirmed in any of the larger studies mentioned earlier in this handbook. The authors explained the incidence by a too low electrode temperature and they advise the readers to perform an *in vivo* calibration\* when they use TC monitoring. [78,95].

Please note that *in vivo* calibration does not make the TC monitor read arterial values, nor does it eliminate the blood flow or any other determinants that TC values depends on. Although an arterial blood gas in many situations is the “gold standard”, there is always a risk of a preanalytical error in the blood sample that is used for the *in vivo* calibration. Furthermore, an *in vivo* calibration requires a new blood sample with every change of measuring site or sensor temperature and the sensor still needs regular calibration due to sensor drift. TC measurements show trends, not absolute values, initially the trends show an actual arterial blood gas value, but it might not be accurate in the end of the measuring period. For more information please refer to the operator manuals [21, 78, 95].

21. Bendjelid K, Schütz N, Stotz M et al. Transcutaneous  $p\text{CO}_2$  monitoring in critically ill adults: Clinical evaluation of a new sensor. *Crit Care Med* 2005; 33, 10: 2203-06.
78. O'Donoghue FJ, Catcheside PG, Ellis EE et al. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: Prevalence and associated factors; *Eur Respir J* 2003; 21: 977- 84.
93. [www.concert-me.com/en/convert/units/pressure/pressure.mm\\*mercury.en.html](http://www.concert-me.com/en/convert/units/pressure/pressure.mm*mercury.en.html)
94. Janssens JP, Perrin E, Bennani I et al. Is continuous transcutaneous monitoring of  $p\text{CO}_2$  (tcp $\text{CO}_2$ ) over 8 h reliable in adults? *Respiratory Medicine* 2001: 95.
95. Cuvelier A, Grigoriu B, Molano LC, Muri J-F et al. Limitations of transcutaneous carbon dioxide measurements for assessing long-term mechanical ventilation. *Chest* 2005; 127: 1744-48.

# Cleaning

## Cleaning

Wipe the following parts gently with a soft cloth moistened with skin antiseptic, e.g. 70 % alcohol:

- sensor head
- cable

*Note:* Use of hand lotion containing isopropanol/propylalcohol and alcohol prior to handling the sensor may damage the cable. To avoid transferring lotion to the cable, dry your hands before handling the sensor.

## Cleaning the exterior

When cleaning the monitor:

- Shut down the monitor
- Use a cloth that has been lightly dampened with soapy water or a mild detergent
- Do not use abrasive cleansers or pads; the finish may become damaged
- Do not use ethanol-based substances or aggressive detergents. Extensive use may cause the plastic to become brittle and cracks may occur

## Cleaning the touch screen

A dry or lightly dampened soft, lint-free cloth may be used to clean the monitor's touch screen. Simply wipe the screen gently to remove fingerprints and/or dirt. To avoid streaking on the screen, an approved screen cleaner is recommended.

## Disinfection

Immerse the sensor and the cable in a 2-3 % aqueous solution of active dialdehydes.

*Warning:* Do not immerse the sensor plug in the disinfection solution, as this will cause the sensor to fail.


*Warning:* Do not heat sterilize as the sensor cannot tolerate temperatures exceeding 70 °C (158 °F), as this will cause the sensor to fail.

## Maintenance of the sensors


### Manufacturer's recommendation for the sensor

For optimum measurements with the E5250 ( $O_2$ ), E5260 ( $CO_2$ ), E5280 ( $O_2/CO_2$ ) and E5480 (neo.  $O_2/CO_2$ ) sensors a weekly change of the sensor membrane is recommended\*. The TC sensor 54 ( $CO_2$ ), TC sensor 84 ( $O_2/CO_2$ ) and TOSCA sensor 92 ( $CO_2/SpO_2$ ) must be remembraned every 14 days.

### Changing the membrane on the E5250-80 sensors




1. Remove the old O-rings:  
Slide the O-ring remover under the O-ring, just above the arrow on the sensor house.



2. Turn the O-ring remover clockwise and counter clockwise to release the two O-rings.  
It is easiest when the sensor is supported against a table.


\*However, in one study the authors write that by more frequent membrane change (i.e. after a maximum of two continuous 8-hour recordings or when the calibration process is unusually long) the agreement between  $PaCO_2$  and  $tcpCO_2$  values increases even more [27].




3. Peel off the old membrane. Note that there are two membranes if it is a combined  $\text{tcpCO}_2/\text{O}_2$  sensor.



4. Clean the sensor surface: Absorb the old electrolyte solution with the cleaning paper in the groove.



5. Rub the sensor measuring surface carefully two or three times to remove the thin layer of silver that has precipitated on the sensor.




6. Apply two drops of the electrolyte solution on the surface of the tc-sensor.

*Note:* Check that the electrolyte solution covers the entire surface without air bubbles.



7.
  - Place the membrane unit on a hard and stable surface.
  - Turn the sensor slowly so that the measuring surface faces downwards. If the electrolyte solution drops off go back to step five.
  - Insert the sensor head into the top of the TC membrane unit.


## Changing the membrane on the E5480 sensor




1. Apply two drops of electrolyte solution to the membranizing tool.

*Note:* Ensure that there are no air bubbles in the electrolyte solution. If air bubbles are present, wait a few seconds and check again.






2. Place the sensor (without the protection cap) in the sensor slot.




3. To remove the old membrane, grip the membraning tool firmly at both ends. Pull in the direction of the arrows until only one arrow is visible in the sensor slot. To click on the new membrane, pull forcefully in the direction of the arrow until the tool is locked and no arrows are visible in the sensor slot.




4. Remove the sensor and wipe off the surplus sensor solution with cleaning paper. Calibrate the sensor twice before use.

## Changing membrane on the tc sensor 54, tc sensor 84 and tc sensor 92



1. Ensure that the sensor is connected to the monitor, which must be turned on. Remove the old membrane retainer ring assembly using the V-shaped notch in the base of the membraning tool. The cable has to point downwards under the membraning tool. Press the membraning tool down while the electrode is kept in place with the other hand and the old membrane is rejected.

*Note:* A new sensor is delivered without membrane. In this case start with step two.




2. Clean the sensor surface with a tissue soaked in clear water. This will also remove the spacer. Dry the sensor surface and make sure that no fibers remain from the tissue.


*Note:* Do not leave an unprepared sensor in air. Proceed immediately with the next step.

SENSOR  
REMEMBRANED  
+ YES +  
- NO -


3. This message appears on the monitor. Leave unanswered until step eight.




4. Lift up the cover of the membraning tool and place two drop of electrolyte solution (that match the sencor numbers) into the center of the retainer ring assembly.




5. Insert the sensor (with its surface pointing downwards) into the preparatory base until it is slightly locked. Do not apply pressure.



6. Close the cover of the membraning tool and press down until the new retainer ring clicks into place. Open the cover, remove sensor and discard membraning tool.



7. Clean excess electrolyte from the side of the sensor.

CALIBRATING  
38 mmHg  
CAL - Gas  
0%  100%

8. Press "+" on the monitor to confirm the new sensor remembraning. The date is stored in the sensor memory.
9. Lift up the lever of the calibration chamber and insert the sensor with its surface pointing downwards as far as it will go. Release the lever. The message: "calibrating sensor" appears. When the calibration is completed the message: "ready to use" appears. The sensor is now ready for measurements.

## List of abbreviations

AARC:	American Association of Respiratory Care
ARDS:	Acute respiratory distress syndrome
BMI:	Body mass index ( $\text{kg}/\text{m}^2$ )
°C:	Degrees Celsius
CPAP:	Continues positive airway pressure
COPD:	Chronic obstructive pulmonary disease
End-tidal $\text{CO}_2$ :	End-tidal concentration of $\text{CO}_2$
°F:	Degrees Fahrenheit
HFJV:	High-frequency jet ventilation
HFOV:	High-frequency oscillatory ventilation
HHb:	Deoxygenated hemoglobin
ICU:	Intensive care unit
IR:	Infrared
kPa:	Kilo Pascal
LED:	Light-emitting diode
mm Hg:	Millimeters of mercury, (the same as Torr)
NPPV:	Non-invasive positive pressure ventilation
NPV:	Negative predictive value
Nm:	Nanometer
$\text{O}_2\text{Hb}$ :	Oxygenated hemoglobin
$\text{PaCO}_2$ :	Arterial $\text{CO}_2$ tension
$\text{PaO}_2$ :	Arterial $\text{O}_2$ tension
$\text{PcaCO}_2$ :	Capillary $\text{CO}_2$ tension
BiPAP:	Bi-level positive airway pressure ventilation
PPV:	Positive predictive value
Prs:	Respiratory resistance measured by oscillation
Rint:	Interrupter technique for measuring respiratory resistance
$\text{SpO}_2$ :	Saturation measured by pulse oximetry
sRaw:	Whole-body plethysmography measurements for specific airway resistance
TC:	Transcutaneous

tcpCO <sub>2</sub> :	Transcutaneous pCO <sub>2</sub>
tcpO <sub>2</sub> :	Transcutaneous pO <sub>2</sub>
tcpCO <sub>2</sub> /O <sub>2</sub> :	Transcutaneous pCO <sub>2</sub> and O <sub>2</sub>
UV:	Ultraviolet light
VD/VT :	Physiological respiratory dead space-to-tidal volume ratio
V/O.:	Ventilation/perfusion ratio
Xrs5:	Respiratory reactance measured by oscillation

# Complementary techniques

The following is a summary of different monitoring techniques that complement transcutaneous monitoring.

## Arterial blood gas samples

Assessment of the alveolar ventilation and arterial oxygen saturation in critically ill patients requires frequent arterial blood gas samples [21].

Arterial blood gas analyses are the gold standard in the ICU and step-down units. However, it is invasive, painful and it can, in very rare situations, result in serious complications (like nerve injury, arterial thrombosis and ischemia leading to necrosis). Furthermore, a blood sample only provides a momentary picture of the  $\text{PaCO}_2/\text{PaO}_2$  status if free of preanalytical errors, it does not show continuous gas values. For neonatal patients it is advisable to minimize the amount of blood samples due to the patient's small blood volume, to reducing the need for blood transfusion that may lead to severe complications. Despite this, arterial blood samples do provide an exact gas status, which may be necessary for the optimum patient surveillance [96,97].

## Pulse oximetry

Pulse oximetry allows monitoring of systemic oxygenation. The technique is widespread and easy to use. Motion like tremors may interrupt the  $\text{SpO}_2$  signal and the measuring site should be without sores, breaks and birthmarks. Finger or toe measurements in patients with poor peripheral circulation may also be problematic. Skin pigmentation and nail polisher may give bias. Most oximeters are accurate within the range of  $\pm 3\text{--}5\%$ , and are considered to be unreliable at levels below 70 %. Due to the flat shape of the oxygen dissociation curve at high oxygen levels, it is not possible to estimate

PaO<sub>2</sub> to detect hyperoxia. The staff should be aware that SpO<sub>2</sub> readings might not be accurate due to elevated levels of carboxyhemoglobin, changes in pH, temperature, 2,3-DPG and pCO<sub>2</sub> levels or abnormal hemoglobin levels. If these factors are taken into consideration, the technique is valuable, cheap and easy to use. However, SpO<sub>2</sub> only shows the oxygenation level and not the carbon dioxide level. Weaning from mechanical ventilation, tidal volume reduction in patients with acute respiratory distress syndrome and management of patients with brain edema require carbon dioxide tension monitoring [98,9,40,19,21].

### **Gastric tonometry and sublingual capnometry**

Gastric tonometry and sublingual capnometry are based on the principle that tissue carbon dioxide is elevated in patients with poor perfusion. The gastric tonometry technique requires an insertion of the specialized nasogastric tube. The method is described as difficult and therefore not often used, e.g. it requires long equilibration time (ideally 90 minutes if the tube balloon is fluid-dependent, and nearly 20 minutes for the gas-dependent type). Histamine type 2 blockers are routinely required to limit the intraluminal generation of carbon dioxide from the gastric acid and enteral nutrition has to stop 2 hours prior to each measurement. The sublingual pCO<sub>2</sub> monitoring has been used in conditions in which the gastrointestinal system has been deprived of adequate perfusion, e.g. early stages of shock. It is “non-invasive” and provides near-instantaneous information. However, there is limited clinical experience with this technique. So far both methods show close relation to decreases in arterial pressure and cardiac index during circulatory or septic shock. They only provide intermittent measurements and they need a nurse to use a probe to acquire each data point. Due to the limited use these techniques will not be discussed any further [4, 64, 99].



## End-tidal $p\text{CO}_2$

End-tidal  $p\text{CO}_2$  monitoring refers to non-invasive measurement of exhaled carbon dioxide concentrations at end-expiration. It is used mainly to verify the endotracheal tube (ETT) position and during cardio-pulmonary resuscitation (CPR). It has become standard of care in the operating room, in some ICUs and is now being increasingly used in the emergency department. The significant inaccuracy introduced into end-tidal  $p\text{CO}_2$  monitoring by the presence of intrapulmonary shunting and dead space ventilation is a problem with the technique. This inaccuracy is also found in patients with intrinsic lung disease, ventilation/perfusion mismatch or in patients with small tidal volumes (e.g. neonates and infants). Studies have shown that in all these patients end-tidal  $p\text{CO}_2$  is less accurate than  $\text{tcpCO}_2$ . Several studies have shown that while end-tidal  $p\text{CO}_2$  significantly increases during one-lung ventilation, neither  $\text{tcpCO}_2$  nor  $\text{PaCO}_2$  show the same changes [21,27,36,46,68,69,100,101].

While both end-tidal and TC measurements are most frequently used instead of  $\text{PaCO}_2$ , they indirectly monitor different elements of carbon dioxide production, transport and elimination. In a comparison study the authors conclude that end-tidal  $p\text{CO}_2$  values may not always accurately reflect  $\text{PaCO}_2$ ; however, end-tidal  $p\text{CO}_2$  measurement still provides information that can be derived from the carbon dioxide waveform and it has a rapid response time [21,102].

## $\text{tcpCO}_2$

$\text{tcpCO}_2$  monitoring (and for neonates also  $\text{tcpO}_2$  monitoring) provides nearly instant and continuous information on the body's peripheral circulation and ability to remove carbon dioxide via the cardiopulmonary system (and deliver oxygen to the tissue). The technique accurately estimates  $\text{PaCO}_2$  in

case of significant cardio-respiratory dysfunction. The monitor can be moved around together with the patient. However, the sensor requires heating and regular calibration, the measuring site should frequently be changed and the sensor must regularly be remembraned. On the other hand TC is non-invasive, easy to use, needs short calibration time and does not involve intubation. Measurements of transcutaneous carbon dioxide during HFJV/HFOV are recommended by manufacturers of these techniques. And  $\text{tcpCO}_2$  trending can validate or limit the need for more costly and higher risk monitoring technology such as arterial blood samples [4,21,102].


### Summary

All techniques have specific advantages and disadvantages. In some patients the non-invasive transcutaneous technique is the most simple and the best choice. It offers relevant and continues non-invasive monitoring of patients with cardio-respiratory disease (of any age). In other segments the best way to monitor can be obtained by combining one or more techniques (TC, ABG,  $\text{SpO}_2$  or end-tidal  $p\text{CO}_2$ ). For example when transcutaneous carbon dioxide monitoring combined with pulse oximetry enhance intermittent invasive arterial blood gas samples. All in all, these four techniques complement rather than exclude each other in reaching the important goal of: Optimizing patient's ventilatory and respiratory status.

4. Hill KM, Klein DG. Transcutaneous carbon dioxide monitoring; Crit Care Nurs Clin N Am 2006; 18: 211-15.
9. Gøthgen IH, Siggaard-Andersen O, Kokholm G. Variations in the hemoglobin-oxygen dissociation curve in 10079 arterial blood samples. Scand. J. Clin. Invest. 1990; 50, suppl. 203: 87-90.
19. Myers CS. Measured results: Pulse oximetry is proving the simple solution to many COPD disease management programs' success. The Journal for Respiratory Care Practitioners 1996; Aug./Sep.: RT 83-86.
21. Bendjelid K, Schütz N, Stotz M *et al.* Transcutaneous  $p\text{CO}_2$  monitoring in critically ill adults: Clinical evaluation of a new sensor. Crit Care Med 2005; 33, 10: 2203-06.
27. Janssens J-A, Laszlo A, Uldry C *et al.*; Non-invasive (transcutaneous) monitoring of  $p\text{CO}_2$  ( $\text{tcpCO}_2$ ) in older adults. Gerontology.2005; 51: 174-78.
36. Wilson J, Russo P, Russo JA, *et al.* Noninvasive monitoring of carbon dioxide in infants and children with congenital heart disease: End-tidal versus transcutaneous techniques. J Intensive Care Med 2005; 20, 5: 291-95.
40. Poets CF. Pulse oximetry vs. transcutaneous monitoring in neonates: Practical aspects. www.bloodgas.org 2003; October: Neonatology.
46. Nosovitch MA, Johnson JO, Tobias JD. Noninvasive intraoperative monitoring of carbon dioxide in children; endtidal versus transcutaneous techniques. Paediatric Anaesthesia 2002; 12: 48-52.
64. Marik PE. Regional carbon dioxide monitoring to assess the adequacy of tissue perfusion. Curr Opin Crit Care 2005; 11: 245-51.
68. Tobias JD. Noninvasive carbon dioxide monitoring during one-lung ventilation: End-tidal versus transcutaneous techniques. Journal of Cardiothoracic and Vascular Anesthesia. 2003; 17, 3: 306-08.
69. Oshibuchi M, Cho S, Hara T *et al.* A comparative evaluation of transcutaneous and end-tidal measurements of  $\text{CO}_2$  in thoracic anesthesia. Anesth analg 2003; 97: 776-79.
96. Wallach SG. Cannulation injury of the radial artery: Diagnosis and treatment algorithm. (Critical care techniques). American Journal of Critical Care 2004; 7, 1.
97. Dar K, Williams T, Aitken R *et al.* Arterial versus capillary sampling for analysis blood gas pressures. BMJ 1995; 310: 24-25.
98. Hamilton AM. The importance of trained staff in pulse oximetry. AARC Times 2005; 29, 12: 39-43.
99. Marik PE. Regional carbon dioxide monitoring to assess the adequacy of tissue perfusion. Curr Opin Crit Care 2005; 11: 245-51.
100. Blanchette T, Dziodzio J. Transcutaneous  $p\text{CO}_2$  and end-tidal  $p\text{CO}_2$  in ventilated adult. Respiratory Care 1992; 92, 3: 204-47.
101. Bhende MS. End-tidal carbon dioxide monitoring in pediatrics: Concepts and technology. J Postgrad Med 2001; 46: 153-56.
102. Hiller SC, Schamberger MS. Editorial: Transcutaneous and end-tidal carbon dioxide analysis: Complimentary monitoring strategies. Journal of Intensive Care Medicine 2005; 20, 5: 307-09.

# Choice of sensor site and temperature

## Neonatal/Pediatric



The diagram is based on market experience and should not be used as general rule

Adult

Respiratory med.	Sleep lab.	OR, ICU, step down	Conscious sedation	
				tc Sensor E5480 (O <sub>2</sub> /CO <sub>2</sub> )
				tc Sensor E5280 (O <sub>2</sub> /CO <sub>2</sub> )
				tc Sensor 92 (SpO <sub>2</sub> /CO <sub>2</sub> )
				tc Sensor E5260 (CO <sub>2</sub> )
				tc Sensor 54 (CO <sub>2</sub> )
				tc Sensor E5250 (O <sub>2</sub> )
				tc Sensor 84 (O <sub>2</sub> /CO <sub>2</sub> )

Figure 1 is a schematic representation of the experimental design, divided into four quadrants. The top-left quadrant is labeled 'Baseline' and shows a single orange bar. The top-right quadrant is also labeled 'Baseline' and shows three bars: orange, blue, and purple. The bottom-left quadrant is labeled 'Training' and shows three bars: orange, blue, and purple. The bottom-right quadrant is labeled 'Transfer' and shows three bars: orange, blue, and purple, with two asterisks indicating significant differences.

\*Shock warning

# ACUTE CARE TESTING